Search Result
Results for "
phospholipases
" in MedChemExpress (MCE) Product Catalog:
12
Biochemical Assay Reagents
6
Isotope-Labeled Compounds
| Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-B0470
-
|
|
Environmental Pollutants
Antibiotic
Phospholipase
Bacterial
|
Infection
Metabolic Disease
Cancer
|
|
Neomycin sulfate, an aminoglycoside antibiotic, exerts antibacterial activity through irreversible binding of the nuclear 30S ribosomal subunit, thereby blocking bacterial protein synthesis. Neomycin sulfate is a known phospholipase C (PLC) inhibitor. Neomycin sulfate potently inhibits both the nuclear translocation of angiogenin and angiogenin-induced cell proliferation and angiogenesis. Neomycin sulfate inhibits IP3-mediated Ca 2+ release, MgATP-dependent Ca 2+ uptake, and electrical excitation-evoked skeletal muscle Ca 2+ transients. Neomycin sulfate depletes gut microbiota in specific mouse models, causes hearing impairment, and kidney damage with prolonged exposure. Neomycin sulfate can be used for the research of cancer .
|
-
-
- HY-13419
-
-
-
- HY-70072
-
|
|
Phospholipase
|
Infection
Inflammation/Immunology
Cancer
|
|
D609, an antitumoural xanthate, is a specific and competitive phosphatidyl choline-specific phospholipase C (PC-PLC) inhibitor with a Ki of 6.4 μM. D609 is an antioxidative protector and has antiviral and anti-inflammatory activity .
|
-
-
- HY-P2812
-
|
PLD
|
Phospholipase
|
Neurological Disease
Inflammation/Immunology
Endocrinology
Cancer
|
|
Phospholipase D, Streptomyces chromofuscus (PLD) is an enzyme of the phospholipase superfamily, which widely exists in bacteria, yeast, plants, animals and viruses, and is often used in biochemical research. Phospholipase D can catalyze the hydrolysis of phosphodiester bonds in glycerophospholipids to produce phosphatidic acid and soluble choline. Phospholipase D is involved in a variety of disease-related processes, including diabetes, atherogenesis, obesity, tumorigenesis, immune response, and neuroendocrine function .
|
-
-
- HY-W019838
-
-
-
- HY-P3029
-
|
PLA2
|
Phospholipase
|
Cardiovascular Disease
Inflammation/Immunology
|
|
Phospholipase A2 (PLA2) is a calcium-dependent, heat-stable enzyme that catalyzes the hydrolysis of glycerophospholipids at the sn-2 position of cellular membranes, thereby releasing Arachidonic Acid (AA) (HY-109590). Phospholipase A2 is a key mediator in the biosynthesis of pro-inflammatory lipid mediators, critically involved in inflammatory processes. Phospholipase A2 can be used for cardiovascular and inflammatory diseases research .
|
-
-
- HY-12598A
-
DHPG
4 Publications Verification
(RS)-3,5-DHPG
|
mGluR
|
Neurological Disease
|
|
DHPG is the agonist for mGluR 1/5 (EC50 for mGluR 1 is 60 nM) that activates the phospholipase C (PLC) pathway, and leads ultimately to the activation of protein kinase C (PKC) .
|
-
-
- HY-136177
-
|
|
Phospholipase
|
Inflammation/Immunology
|
|
Tris(2,4-di-tert-butylphenyl)phosphate is an active compound from the leaves of Vitex negundo L. shows anti-inflammatory activity with evidence of inhibition for secretory Phospholipase A2 (sPLA2) through molecular docking .
|
-
-
- HY-111376
-
-
-
- HY-N9480
-
|
SM-345431
|
Phospholipase
Bacterial
|
Infection
Cancer
|
|
Vinaxanthone (SM-345431) is a potent and selective semaphorin3A, phospholipase C (PLC) and FabI inhibitor, with IC50s of 0.1-0.2 μM and 0.9 mM for semaphorin3A and FabI. Vinaxanthone inhibits the substrate (t-o-NAC thioester) and the cofactor (NADPH) with Kis of 3.1 μM and 1.0 μM, respectively. Vinaxanthone can be used to handle infections caused by multidrug-resistant pathogens .
|
-
-
- HY-W039315
-
|
|
Biochemical Assay Reagents
|
Metabolic Disease
|
2,5-Anhydro-D-mannitol, 97% is an antimetabolic fructose analogue. 2,5-Anhydro-D-mannitol, 97% depletes intracellular ATP, reduces oxygen consumption, regulates substrate oxidation, increases phosphomonoester levels, decreases inorganic phosphate levels, and promotes the release of intracellular calcium from intracellular calcium stores via phospholipase C-dependent activity in hepatocytes .
|
-
-
- HY-150520
-
|
|
Antibiotic
Phospholipase
|
Infection
Cancer
|
|
Neomycin, an aminoglycoside antibiotic, exerts antibacterial activity through irreversible binding of the nuclear 30S ribosomal subunit, thereby blocking bacterial protein synthesis. Neomycin is a known phospholipase C (PLC) inhibitor. Neomycin potently inhibits both the nuclear translocation of angiogenin and angiogenin-induced cell proliferation and angiogenesis. Neomycin inhibits IP3-mediated Ca 2+ release, MgATP-dependent Ca 2+ uptake, and electrical excitation-evoked skeletal muscle Ca 2+ transients. Neomycin depletes gut microbiota in specific mouse models, causes hearing impairment, and kidney damage with prolonged exposure. Neomycin can be used for the research of cancer .
|
-
-
- HY-17448
-
-
-
- HY-18540
-
KT109
1 Publications Verification
|
MAGL
DAGL
|
Metabolic Disease
Inflammation/Immunology
|
|
KT109 is a potent and an isoform-selective inhibitor of diacylglycerol lipase-β (DAGLβ) with an IC50 of 42 nM. KT109 has ~60-fold selectivity for DAGLβ over DAGLα. KT109 shows inhibitory activity against PLA2G7 (IC50=1 µM). KT109 shows negligible activity against FAAH, MGLL, ABHD11, and cytosolic phospholipase A2 (cPLA2 or PLA2G4A). KT109 perturbs a lipid network involved in macrophage inflammatory responses and lowers 2-Arachidonoylglycerol (HY-W011051), Arachidonic acid (HY-109590) and eicosanoids in mouse peritoneal macrophages .
|
-
-
- HY-N1393
-
|
NSC 3778; O-Methylsalicylic acid; Salicylic acid methyl ether
|
Carbonic Anhydrase
Phospholipase
|
Cardiovascular Disease
|
|
2-Methoxybenzoic acid (NSC 3778; O-Methylsalicylic acid; Salicylic acid methyl ether) is a natural compound with potential salicylate-like effect. 2-Methoxybenzoic acid inhibits carbonic anhydrase activity, elevates intraplatelet cyclic guanosine monophosphate level, and suppresses cytosolic phospholipase A2 phosphorylation. 2-Methoxybenzoic acid suppresses platelet reactivity, including decreased spreading, retraction, and aggregation in platelets. 2-Methoxybenzoic acid ameliorates arterial thrombosis in a dose-dependent manner without affecting normal hemostasis in mice. 2-Methoxybenzoic acid can be used for the research of arterial thrombosis .
|
-
-
- HY-111919
-
|
|
Phospholipase
Fungal
|
Infection
|
|
3-Nitrocoumarin is an inhibitor for phospholipase C that blocks the generation of inositol triphosphate (IP3), thereby affecting the calcium signaling pathway .
|
-
-
- HY-108607
-
|
Palmityltrifluoromethylketone
|
Phospholipase
|
Inflammation/Immunology
|
|
PACOCF3 (Palmityltrifluoromethylketone) is a selective phospholipase A2 inhibitor with an IC50 of 3.8 μM. PACOCF3 alters Ca 2+ signaling in renal tubular cells .
|
-
-
- HY-19151
-
|
IS-741
|
Integrin
Phospholipase
|
Inflammation/Immunology
|
|
Fuzapladib (IS-741), an orally active leukocyte-function-associated antigen type 1 (LFA-1) activation inhibitor, is a leukocyte adhesion molecule. Fuzapladib is also a phospholipase A2 (PLA2) inhibitor. Fuzapladib exerts anti-inflammatory effects by inhibiting leukocyte migration into the inflammatory site .
|
-
-
- HY-100983
-
|
|
PKC
|
Cancer
|
|
Protein kinase inhibitor H-7 dihydrochloride is a potent PKC (protein kinase C) inhibitor. At 100 μM, Protein kinase inhibitor H-7 dihydrochloride completely inhibits both TPA (skin tumour promoter, 12-O-tetradecanoylphorbol-13-acetate) and phospholipase C-induced ODC (ornithine decarboxylase) .
|
-
-
- HY-119019
-
-
-
- HY-14952
-
|
PLA-695
|
Phospholipase
|
Inflammation/Immunology
Cancer
|
|
Giripladib (PLA-695) is a indole-based inhibitor of cytosolic phospholipase A2 (cPLA2). Giripladib can be used for osteoarthritis and breast cancer research .
|
-
-
- HY-N1773
-
|
|
Others
|
Cancer
|
|
5,7,3' -tri-O-Methyl (-)-epicatechin (Compound 13) is a phospholipase Cγ1 (PLCγ1) inhibitor. 5,7,3' -tri-o-methyl (-)-epicatechin has a methylene dioxy benzene ring and can express inhibitory activity against PLCγ1. 5,7,3' -tri-O-Methyl (-)-epicatechin can be used in the study of chemotherapy and chemopexic agents for cancer .
|
-
-
- HY-P2812A
-
|
|
Endogenous Metabolite
|
Metabolic Disease
|
|
Phospholipase D, peanut is an important signaling enzyme in mammalian cells. Phospholipase D, peanut catalyzes the hydrolysis of phosphatidylcholine to produce phosphatidic acid (PA) and choline .
|
-
-
- HY-P10447
-
|
Fengycin IX; SNA-60-367-3
|
Phospholipase
Fungal
|
Infection
|
|
Plipastatin A1 (Fengycin IX; SNA-60-367-3) is a lipopeptide with phospholipase A2 inhibitory activity. Plipastatin A1 inhibits conidial germination of Botrytis cinerea in vitro and reduces the incidence of gray mold on tomato leaves. Plipastatin A1 is applicable to research related to gray mold [1][2].
|
-
-
- HY-P3029A
-
|
PLA2, Crotalus adamanteus Venom
|
Phospholipase
|
Others
|
|
Phospholipase A2, Crotalus adamanteus Venom (PLA2) catalyzes the hydrolysis of the sn-2 position of membrane glycerophospholipids to liberate arachidonic acid (AA). Phospholipase A2, Crotalus adamanteus Venom is a member of the class of heat-stable, calcium-dependent enzymes, is often used in biochemical studies .
|
-
-
- HY-108609
-
-
-
- HY-W100403
-
|
Choline p-toluenesulfonate
|
Phospholipase
|
Others
|
|
Choline tosylate (Choline p-toluenesulfonate) is an intermediate and also a substrate of choline acetyltransferase (CHAT). Choline tosylate inhibits phospholipase A2 and phospholipase C .
|
-
-
- HY-122756
-
-
-
- HY-107393
-
|
|
Phospholipase
|
Inflammation/Immunology
|
|
LY-311727 is a potent secretory non-pancreatic phospholipase A2 (sPLA2) inhibitor (IC50 <1 μM for group IIA sPLA2). sPLA2 is an important proinflammatory enzyme .
|
-
-
- HY-P2705
-
|
|
Endogenous Metabolite
|
Others
|
|
Mastoparan X is a GTP-binding regulatory protein (G protein)-activating peptide, and a tetradecapeptide from wasp venom. Mastoparan X acts function by the direct activation of G protein that couple to phospholipase C to cause secretion from various kinds of cells .
|
-
-
- HY-116301
-
|
|
Phospholipase
|
Inflammation/Immunology
|
|
CAY10502 is a potent, calcium-dependent cytosolic phospholipase A2 α (cPLA2α) inhibitor with an IC50 of 4.3 nM for isolated enzyme. CAY10502 can be used in the research of retinopathy and inflammatory diseases .
|
-
-
- HY-19151A
-
|
IS-741 sodium
|
Integrin
Phospholipase
|
Inflammation/Immunology
|
|
Fuzapladib (IS-741) sodium, an orally active leukocyte-function-associated antigen type 1 (LFA-1) activation inhibitor, is a leukocyte adhesion molecule. Fuzapladib sodium is also a phospholipase A2 (PLA2) inhibitor. Fuzapladib sodium exerts anti-inflammatory effects by inhibiting leukocyte migration into the inflammatory site .
|
-
-
- HY-145653
-
-
-
- HY-W612338
-
|
9-ONA
|
Acetyl-CoA Carboxylase
|
Inflammation/Immunology
|
|
9-Oxononanoic acid (9-ONA) is an orally active acetyl-CoA carboxylase inhibitor. 9-Oxononanoic acid inhibits acetyl-CoA carboxylase via accumulation of long-chain acyl-CoA. 9-Oxononanoic acid increases carnitine palmitoyltransferase, isocitrate dehydrogenase and glucose 6-phosphate dehydrogenase activity to elevate β-oxidation and support NADPH (HY-113324) supplyactivity. 9-Oxononanoic acid stimulates phospholipase A2 activity via post-translational, non-transcriptional mechanisms. 9-Oxononanoic acid can be used for the research of atherothrombosis .
|
-
-
- HY-120441
-
-
-
- HY-70083
-
-
-
- HY-P2817
-
|
PLCs
|
Phospholipase
|
Infection
Metabolic Disease
|
|
Phospholipase C (PLCs) is a class of phospholipases. Phospholipase C participates in cellular signaling and regulation by virtue of its ability to hydrolyze membrane phospholipids into di-acyl-glycerol (DAG) and inositol triphosphate (IP3), which further causes the activation of other signaling pathways involved in various processes, including immune response .
|
-
-
- HY-155342
-
|
|
Phospholipase
|
Inflammation/Immunology
|
|
A3373, a novel chemical inhibitor of Phospholipase D1 (PLD1) and PLD2, with IC50 of 325 nM and 15.15?μM, respectively, inhibits LPS-induced immune response and plays important roles in autoimmune arthritis, bone demineralization and osteoclastogenesis .
|
-
-
- HY-145384
-
|
|
Phospholipase
|
Inflammation/Immunology
|
|
ROC-0929 (compound 13a) is a potent and selective inhibitor of secreted phospholipases A2 (sPLA2s) with an IC50 of 80 nM, specially targeting hGX. ROC-0929 inhibits the phosphorylation of ERK1/2 and p-38. Secreted phospholipases A2 (sPLA2s) are a family of disulfide-rich, Ca 2+-dependent enzymes that hydrolyze the sn-2 position of glycero-phospholipids to release a fatty acid and a lysophospholipid. ROC-0929 has the potential for researching inflammation related diseases .
|
-
-
- HY-116018
-
|
|
Phospholipase
|
Neurological Disease
Inflammation/Immunology
Cancer
|
|
FKGK11 is a potent and selective inhibitor of GVIA iPLA2 (Group VIA calcium-independent phospholipase A2). FKGK11 can be used for the research of ovarian cancer and neurological disorders such as peripheral nerve injury and multiple sclerosis .
|
-
-
- HY-P10053
-
|
|
Phospholipase
|
Metabolic Disease
|
|
sPLA2-IIA Inhibitor is a cyclic pentapeptide analog of FLSYK (cyclic 2-Nal-Leu-Ser-2-Nal-Arg (c2)), that binds to hGIIA (human IIA phospholipase A2) and inhibits its hydrolytic ability. sPLA2 is a member of the esterase superfamily that catalyzes the hydrolysis of the ester bond at the sn-2 position of glycerophospholipids, releasing free fatty acids such as arachidonic acid and lysophospholipids .
|
-
-
- HY-129944
-
|
|
Phospholipase
|
Inflammation/Immunology
|
|
MJ33-OH is a metabolite of MJ33. MJ33 is an active-site-directed, specific, competitive, and reversible phospholipase A2 (PLA2) inhibitor. MJ33 blocks the calcium-independent phospholipase A2 (iPLA2) activity of Prdx6 .
|
-
-
- HY-125157
-
-
-
- HY-P2812B
-
|
|
Phospholipase
|
Cardiovascular Disease
Neurological Disease
Inflammation/Immunology
Cancer
|
|
Phospholipase D, cabbage is an enzyme of the phospholipase superfamily. Phospholipase D, cabbage is widely found in bacteria, yeast, plants, animals and viruses and is often used in biochemical research. Phospholipase D, cabbage can catalyze the hydrolysis of the phosphodiester bond of glycerophospholipids to produce phosphatidic acid and soluble choline. Phospholipase D, cabbage is involved in a variety of disease-related processes, including diabetes, atherosclerosis, obesity, tumorigenesis, immune response and neuroendocrine function .
|
-
-
- HY-148388
-
|
N-Stearoyl-D-sphingomyelin
|
Phospholipase
|
Cancer
|
|
N-Stearoylsphingomyelin (N-Stearoyl-D-sphingomyelin) is a sphingolipid, which can inhibit Phospholipase Cδ1 (PLCδ1) .
|
-
-
- HY-19920
-
-
-
- HY-117168
-
|
|
Endogenous Metabolite
|
Metabolic Disease
|
|
1,2-Dilinoleoyl-sn-glycerol is a diacylglycerol (DAG) with linoleic acid (HY-N0729) (18:2) side chains attached at both the sn-1 and sn-2 positions . 1,2-Dilinoleoyl-sn-glycerol can be prepared from L-dilinoleoylphosphatidylcholine via hydrolysis with phospholipase C .
|
-
-
- HY-118994
-
|
|
Phospholipase
|
Neurological Disease
|
|
ARN19874 is a selective, reversible uncompetitive N-acylphosphatidylethanolamine phospholipase D (NAPE-PLD) activity inhibitor with an IC50 of ~34 μM .
|
-
-
- HY-137311
-
-
-
- HY-N1450
-
|
|
Phospholipase
|
Cancer
|
|
Aristolochic acid C is a derivative of Aristolochic acid. Aristolochic acid is a phospholipase A2 (PLA2) inhibitor, which disrupts cortical microtubule arrays and root growth in Arabidopsis .
|
-
- HY-N8610
-
|
|
Phosphatase
|
Inflammation/Immunology
|
|
Uralsaponin D is a saponin that can be isolated from Glycyrrhiza inflata. Uralsaponin D inhibits phospholipase A2 (PLA2) with an IC50 value of 32.2 μM .
|
-
- HY-23909
-
|
DEDA
|
Phospholipase
|
Inflammation/Immunology
|
|
7,7-Dimethyl-(5Z,8Z)-eicosadienoic acid (DEDA), a phospholipase inhibitor, is a non-metabolizable analog of arachidonic or eicosadienoic acid. 7,7-Dimethyl-(5Z,8Z)-eicosadienoic acid (DEDA) inhibits P388D1 cell phospholipase A2 (PLA2) (IC50 = 16 µM) and snake venom PLA2 (IC50 = 14 µM) .
|
-
- HY-118725
-
|
|
Phospholipase
|
Inflammation/Immunology
|
|
Luffariellolide is an inhibitor of human synovial fluid phospholipase A2 (HSF-PLA2) (IC50=5 μM). Luffariellolide effectively inhibits phorbol ester (PMA)-induced ear edema (ED50=50 μg/ear) .
|
-
- HY-136177R
-
|
|
Reference Standards
Phospholipase
|
Inflammation/Immunology
|
|
Tris(2,4-di-tert-butylphenyl)phosphate (Standard) is the analytical standard of Tris(2,4-di-tert-butylphenyl)phosphate. This product is intended for research and analytical applications. Tris(2,4-di-tert-butylphenyl)phosphate is an active compound from the leaves of Vitex negundo L. shows anti-inflammatory activity with evidence of inhibition for secretory Phospholipase A2 (sPLA2) through molecular docking .
|
-
- HY-119094
-
|
|
Phospholipase
|
Inflammation/Immunology
|
|
WAY-196025 is a selective and orally active indole cytosolic phospholipase A2 alpha (cPLA2α) inhibitor with an IC50 of 0.01μM and a Kd of 0.013 μM. WAY-196025 can inhibit the production of prostaglandins (such as PGE2) and leukotrienes (such as LTB4), and reduce the release of inflammatory mediators. WAY-196025 can be used for the researches of inflammation and immunology, such as asthma .
|
-
- HY-171909A
-
|
GroPIns-4-P disodium
|
Adenylate Cyclase
ROCK
|
Cancer
|
|
Glycerophosphoinositol 4-phosphate (GroPIns-4-P) disodium is a metabolite of phospholipase A and an inhibitor of adenylylcyclase. Glycerophosphoinositol 4-phosphate disodium can regulate cAMP-dependent cellular functions. Glycerophosphoinositol 4-phosphate disodium can also induce the formation of membrane ruffles and stress fibers in serum-starved Swiss 3T3 cells by activating the small GTPases Rac and Rho, respectively. Glycerophosphoinositol 4-phosphate disodium can be used in research on cancer cell motility and invasiveness .
|
-
- HY-129944A
-
|
|
Phospholipase
|
Inflammation/Immunology
|
|
MJ33-OH lithium is a metabolite of MJ33. MJ33 is an active-site-directed, specific, competitive, and reversible phospholipase A2 (PLA2) inhibitor. MJ33 blocks the calcium-independent phospholipase A2 (iPLA2) activity of Prdx6 .
|
-
- HY-113560
-
-
- HY-176085
-
|
|
Phospholipase
|
Others
|
|
Heptanoyl thio-PC is a sn-2 thiol-labeled Phospholipase A2 (HY-P3029) (PLA2) substrate that can be used to detect the activity of Phospholipase A2 .
|
-
- HY-116671
-
|
|
Phospholipase
|
Others
|
|
Folipastatin is a potent inhibitor of phospholipase A2 with an IC50 of 39 μM. Folipastatin is a new depsidone compound from Aspergillus unguis .
|
-
- HY-162368
-
|
|
Phospholipase
|
Others
|
|
cPLA2α-IN-2 (Compound 122) is an inhibitor of cytosolic phospholipase A2α (cPLA2α) .
|
-
- HY-W414749
-
|
1-Octanoyl-sn-glycero-3-phosphocholine
|
Biochemical Assay Reagents
|
Others
|
|
08:0 Lyso PC (1-Octanoyl-sn-glycero-3-phosphocholine) is a lysolecithin that can be hydrolyzed by Phospholipase A2 (HY-P3029) .
|
-
- HY-127008
-
|
|
Fluorescent Dye
|
Others
|
|
N-Butylfluorescein is an alkyl-substituted fluorescein, can be used for synthesis of fluorogenic substrates for assaying phosphatidylinositol-specific phospholipase C .
|
-
- HY-155343
-
|
|
Phospholipase
|
Cancer
|
|
A4333 is biotinylated compound of A3373 (HY-155342) that inhibits Phospholipase D1 (PLD1), but not PLD2. A4333 plays an important role in antitumor activity .
|
-
- HY-W396889
-
-
- HY-P10658
-
|
|
Phospholipase
|
Others
|
|
ARF1 (2-17) inhibits both ARF-independent (PLC-β) and ARF-dependent (PLD) pathways. ARF1 (2-17) inhibits GTP-γ-S-stimulated PLD activity, phospholipase C-β (PLC-β), and exocytosis .
|
-
- HY-133148
-
|
|
Phospholipase
|
Inflammation/Immunology
|
|
Lp-PLA2-IN-2 is a potent and selective lipoprotein-associated phospholipase A2 (Lp-PLA2) inhibitor, with an IC50 0f 120 nM for recombinant human Lp-PLA2 .
|
-
- HY-108607R
-
|
Palmityltrifluoromethylketone (Standard)
|
Phospholipase
Reference Standards
|
Inflammation/Immunology
|
|
PACOCF3 (Standard) is the analytical standard of PACOCF3. This product is intended for research and analytical applications. PACOCF3 (Palmityltrifluoromethylketone) is a selective phospholipase A2 inhibitor with an IC50 of 3.8 μM. PACOCF3 alters Ca2+ signaling in renal tubular cells .
|
-
- HY-116730
-
|
|
Reactive Oxygen Species (ROS)
|
Others
|
|
CHS-111 is a benzyl indazole inhibitor of superoxide anion O 2- generation. CHS-111 inhibits the cell migration, and reduces the formyl-Met-Leu-Phe- but not phorbol ester-stimulated phospholipase D activity, with the IC50 of 3.9 μM .
|
-
- HY-19151C
-
|
IS-741 calcium
|
Integrin
Phospholipase
|
Inflammation/Immunology
|
|
Fuzapladib calcium, an orally active leukocyte-function-associated antigen type 1 (LFA-1) activation inhibitor, is a leukocyte adhesion molecule. Fuzapladib calcium is also a phospholipase A2 (PLA2) inhibitor. Fuzapladib calcium exerts anti-inflammatory effects by inhibiting leukocyte migration into the inflammatory site .
|
-
- HY-142670
-
|
|
Phospholipase
|
Neurological Disease
Metabolic Disease
|
|
Lp-PLA2-IN-5 is a potent inhibitor of lipoprotein-associated phospholipase A2 (Lp-PLA2). Lp-PLA2 previously known as platelet- activating factor acetylhydrolase (PAF-AH), is a phospholipase A2 enzyme involved in hydrolysis of lipoprotein lipids or phospholipids. Lp-PLA2-IN-5 has the potential for the research of diseases associated with the activity of Lp-PLA2, for example atherosclerosis, Alzheimer's disease (extracted from patent WO2021228159A1, compound 32) .
|
-
- HY-142669
-
|
|
Phospholipase
|
Neurological Disease
Metabolic Disease
|
|
Lp-PLA2-IN-4 is a potent inhibitor of lipoprotein-associated phospholipase A2 (Lp-PLA2). Lp-PLA2 previously known as platelet- activating factor acetylhydrolase (PAF-AH), is a phospholipase A2 enzyme involved in hydrolysis of lipoprotein lipids or phospholipids. Lp-PLA2-IN-4 has the potential for the research of diseases associated with the activity of Lp-PLA2, for example atherosclerosis, Alzheimer's disease (extracted from patent WO2021228159A1, compound 38) .
|
-
- HY-142779
-
|
|
Phospholipase
|
Neurological Disease
Metabolic Disease
|
|
Lp-PLA2-IN-11 is a potent inhibitor of lipoprotein-associated phospholipase A2 (Lp-PLA2). Lp-PLA2 previously known as platelet- activating factor acetylhydrolase (PAF-AH), is a phospholipase A2 enzyme involved in hydrolysis of lipoprotein lipids or phospholipids. Lp-PLA2-IN-11 has the potential for the research of diseases associated with the activity of Lp-PLA2, for example atherosclerosis, Alzheimer's disease (extracted from patent WO2014114249A1, compound E145) .
|
-
- HY-142778
-
|
|
Phospholipase
|
Neurological Disease
Metabolic Disease
|
|
Lp-PLA2-IN-10 is a potent inhibitor of lipoprotein-associated phospholipase A2 (Lp-PLA2). Lp-PLA2 previously known as platelet- activating factor acetylhydrolase (PAF-AH), is a phospholipase A2 enzyme involved in hydrolysis of lipoprotein lipids or phospholipids. Lp-PLA2-IN-10 has the potential for the research of neurodegenerative-related diseases such as Alzheimer's disease (AD), glaucoma, age-related macular degeneration (AMD), or cardiovascular diseases including atherosclerosis (extracted from patent WO2022001881A1, compound 4) .
|
-
- HY-19151B
-
|
IS-741 potassium
|
Integrin
Phospholipase
|
Inflammation/Immunology
|
|
Fuzapladib (IS-741) potassium, an orally active leukocyte-function-associated antigen type 1 (LFA-1) activation inhibitor, is a leukocyte adhesion molecule. Fuzapladib potassium is also a phospholipase A2 (PLA2) inhibitor. Fuzapladib potassium exerts anti-inflammatory effects by inhibiting leukocyte migration into the inflammatory site .
|
-
- HY-100983R
-
|
|
Reference Standards
PKC
|
Cancer
|
|
Protein kinase inhibitor H-7 (dihydrochloride) (Standard) is the analytical standard of Protein kinase inhibitor H-7 (dihydrochloride). This product is intended for research and analytical applications. Protein kinase inhibitor H-7 dihydrochloride is a potent PKC (protein kinase C) inhibitor. At 100 μM, Protein kinase inhibitor H-7 dihydrochloride completely inhibits both TPA (skin tumour promoter, 12-O-tetradecanoylphorbol-13-acetate) and phospholipase C-induced ODC (ornithine decarboxylase) .
|
-
- HY-N14050
-
-
- HY-N14292
-
|
|
Phospholipase
|
Infection
|
|
Hispidospermidin is a phospholipase C inhibitor found in Chaetosphaeronema hispidulum .
|
-
- HY-N14101
-
-
- HY-108132
-
-
- HY-W019838R
-
-
- HY-149654
-
-
- HY-19041
-
-
- HY-137311A
-
-
- HY-N14103
-
|
|
Phospholipase
|
Others
|
|
Cinatrin C1 is a phospholipase A2 (PLA2) inhibitor that can be extracted from Circinotrichum falcatisporum RF-641 .
|
-
- HY-158734
-
|
MγLnFP
|
Phospholipase
|
Others
|
|
Methyl γ-linolenyl fluorophosphonate (MγLnFP) is a close analog of a well-characterized, irreversible inhibitor of phospholipases, methyl arachidonyl fluorophosphonate (MAFP) .
|
-
- HY-W800785
-
|
1-palMitoyl-2-(10,12-tricosadiynoyl)-sn-glycero-3-phosphocholine
|
Liposome
|
Cancer
|
|
16:0-23:2 Diyne PC is a phospholipase-mediated hydrolyzed phosphocoline with palmitic acid (16:0) and Pentacosa-10,12-diynoic acid for tails.
|
-
- HY-115855
-
-
- HY-182680
-
|
|
Phospholipase
|
Inflammation/Immunology
|
|
Manoalogue is an irreversible secretory phospholipase A2 (sPLA2) inhibitor. Manoalogue covalently modifies K94 of bee venom phospholipase A2 (bvPLA2) to inactivate the enzyme and shows selective inhibition on bvPLA2. Manoalogue can suppress PLA2-mediated contractions of guinea pig lung pleural strips. Manoalogue is used for sPLA2 mechanism and respiratory physiology research .
|
-
- HY-171909
-
|
GroPIns-4-P
|
Adenylate Cyclase
ROCK
|
Cancer
|
|
Glycerophosphoinositol 4-phosphate (GroPIns-4-P) is a metabolite of phospholipase A and an inhibitor of adenylylcyclase. Glycerophosphoinositol 4-phosphate can regulate cAMP-dependent cellular functions. Glycerophosphoinositol 4-phosphate can also induce the formation of membrane ruffles and stress fibers in serum-starved Swiss 3T3 cells by activating the small GTPases Rac and Rho, respectively. Glycerophosphoinositol 4-phosphate can be used in research on cancer cell motility and invasiveness .
|
-
- HY-W414803
-
-
- HY-P2817B
-
|
|
Biochemical Assay Reagents
|
Metabolic Disease
|
|
Phospholipase C, Bacillus cereus (EC 3.1.4.3) is induced by thrombin and platelet-activating factor, forming 1,2-diacylglycerol and phosphatidic acid. Phospholipase C, Bacillus cereus (EC 3.1.4.3) hydrolyzes the phosphate bond on phosphatidylcholine and other glycerophospholipids yielding diacylglycerol. Phospholipase C, Bacillus cereus (EC 3.1.4.3) hydrolyzes the phosphate bonds of sphingomyelin, cardiolipin, choline plasmalogen and ceramide phospholipids.
|
-
- HY-182434
-
|
|
Phosphatase
FAP
|
Inflammation/Immunology
|
|
CL 118326 is a potent, selective, competitive inhibitor of mammalian pancreatic phospholipase A2 (PLA2) and a weak antagonist of platelet-activating factor receptor (PAF receptor). CL 118326 competitively inhibits mammalian pancreatic PLA2 (porcine: IC50 = 1.55 μg/mL), and shows no activity against snake venom or bee venom PLA2. CL 118326 inhibits PAF-induced and thrombin-induced platelet aggregation, as well as the release of leukotriene (LTC4) and histamine from basophil-enriched leukocytes. CL 118326 can be used for research on inflammation and allergic reactions .
|
-
- HY-P991964
-
|
Rendomab-B49
|
Endothelin Receptor
|
Cancer
|
|
Rendomab B4 is a monoclonal antibody targeting ETB. Rendomab B4 preferentially binds to ETB in the active conformational state and exhibits selectivity for ETB on melanoma cells. Rendomab B4 inhibits the G protein-dependent phospholipase C (PLC) pathway, blocks ET-3-induced Gαi/o-mediated inhibition of adenylate cyclase, and does not affect the activation of the ERK1/2 pathway. Rendomab B4 is applicable to melanoma-related research .
|
-
- HY-128061
-
|
|
Phospholipase
Reactive Oxygen Species (ROS)
|
Inflammation/Immunology
|
|
CDIBA is a cytosolic phospholipase A2 (cPLA2) inhibitor. CDIBA inhibits the activation of cPLA2 in rat diaphragm tissue. CDIBA reduces the level of mitochondrial reactive oxygen species in rat diaphragm tissue after prolonged mechanical ventilation. CDIBA attenuates protein degradation, muscle atrophy and decreased muscle strength in the diaphragm of rats after prolonged mechanical ventilation. CDIBA can be used in studies related to ventilator-induced diaphragmatic dysfunction .
|
-
- HY-E70616
-
|
|
Bacterial
|
Infection
|
|
Secreted Phospholipase A2-IIA, Human (EC 3.1.1.4), belongs to the family of antimicrobial peptides, hydrolyzes phospholipids to liberate lysophospholipids and fatty acids. Secreted Phospholipase A2-IIA, Human (EC 3.1.1.4) efficiently hydrolyzes bacterial membranes .
|
-
- HY-P2139
-
|
|
Neurokinin Receptor
Phospholipase
|
Others
|
|
Ranakinin is a NK1R agonist. Ranakinin inhibits the binding of selective NK1 radioligands to NK1 receptors. Ranakinin activates phospholipase C (Phospholipase C), thereby enhancing polyphosphoinositide hydrolysis. Ranakinin stimulates inositol phosphate production and reduces membrane polyphosphoinositide levels. Ranakinin stimulates corticosterone and aldosterone secretion .
|
-
- HY-P3029C
-
|
|
Phospholipase
|
Metabolic Disease
|
|
Phospholipase A2, Porcine (EC 3.1.1.4) hydrolyzes the β-ester bond of zwitterionic glycerophospholipids. Preferred substrates are phosphatidylcholine, phosphatidylethanolamine, and their plasmalogen analogues. Phosphatidylinositol and phosphatidylserine are also hydrolyzed. Phospholipase A2specifically recognizes the sn-2 acyl bond of phospholipids and catalytically hydrolyzes the bond releasing arachidonic acid and lysophospholipids.
|
-
- HY-P3029B
-
|
|
Phospholipase
|
Metabolic Disease
|
|
Phospholipase A2, Streptomyces violaceoruber (EC 3.1.1.4) hydrolyzes the β-ester bond of zwitterionic glycerophospholipids. Preferred substrates are phosphatidylcholine, phosphatidylethanolamine, and their plasmalogen analogues. Phosphatidylinositol and phosphatidylserine are also hydrolyzed. Phospholipase A2specifically recognizes the sn-2 acyl bond of phospholipids and catalytically hydrolyzes the bond releasing arachidonic acid and lysophospholipids.
|
-
- HY-P3029E
-
|
|
Biochemical Assay Reagents
|
Metabolic Disease
|
|
Phospholipase A2, Naja mossambica mossambica (EC 3.1.1.4) hydrolyzes the β-ester bond of zwitterionic glycerophospholipids. Preferred substrates are phosphatidylcholine, phosphatidylethanolamine, and their plasmalogen analogues.
|
-
- HY-N14104
-
|
|
Phospholipase
|
Others
|
|
Cinatrin C2 is a phospholipase A2 (PLA2) inhibitor with an IC50 of 800 μM and can be extracted from Circinotrichum falcatisporum RF-641 .
|
-
- HY-N14105
-
|
|
Phospholipase
|
Others
|
|
Cinatrin C3 is a phospholipase A2 (PLA2) inhibitor with an IC50 of 70 μM and can be extracted from Circinotrichum falcatisporum RF-641 .
|
-
- HY-138871
-
-
- HY-159656
-
|
|
PNPLA3
|
Others
|
|
PNPLA3 modifier 1 (compound 10) is a Patatin-like phospholipase domain-containing protein 3 (pnpla3) modifier, with a geometric mean EC50 of 4.9 nM .
|
-
- HY-136271
-
|
|
Phospholipase
NADPH Oxidase
p38 MAPK
Akt
NF-κB
AP-1
Reactive Oxygen Species (ROS)
|
Cardiovascular Disease
Inflammation/Immunology
Cancer
|
|
MJ-33 is a competitive phospholipase A₂ (PLA₂) inhibitor with an IC50 of 0.3 μM. MJ-33 inhibits the activation of NOX2 by blocking the PLA₂ activity of Prdx6, thereby reducing the production of ROS. MJ-33 effectively inhibits the activity of acidic PLA₂ (pH 4.0), reduces the degradation of pulmonary surfactant phosphatidylcholine (PC), but has no effect on alkaline PLA₂ (pH 8.5). MJ-33 significantly alleviates lung oxidative damage induced by ischemia-reperfusion (I/R). MJ-33 significantly inhibits the invasive, migratory and adhesive abilities of prostate cancer cells by suppressing the MAPK, AKT, NF-κB and AP-1 signaling pathways. MJ-33 can be used to study ROS-related diseases and prostate cancer .
|
-
- HY-112738
-
|
|
Phospholipase
|
Inflammation/Immunology
|
|
AX048 is an inhibitor for calcium-dependent phospholipase A2 cPLA2 with a XI(50) of 0.022 mole fraction and reveals an antihyperalgesic efficacy .
|
-
- HY-W012595A
-
|
trans-Benzalacetone
|
Environmental Pollutants
Phospholipase
|
Inflammation/Immunology
|
|
trans-Benzylideneacetone (trans-Benzalacetone), a metabolite of gram-negative entomopathogenic bacterium Xenorhabdus nematophila, is an enzyme inhibitor against phospholipase A2 (PLA2). trans-Benzylideneacetone is an immunosuppressant .
|
-
- HY-106555
-
|
|
Phospholipase
|
Inflammation/Immunology
|
|
Protizinic acid is an orally active non-steroidal antiinflammatory agent with antiinflammatory and antipyretic activity. Protizinic acid inhibits phospholipase A2 (PLA2) activity, and the IC50 value is 210 μM .
|
-
- HY-W800784
-
|
|
Liposome
|
Cancer
|
|
23:2 Diyne PE [DC(8,9)PE] is a phospholipase-mediated hydrolyzed phosphocoline with palmitic acid (16:0) and Pentacosa-10,12-diynoic acid for tails.
|
-
- HY-P3029D
-
|
|
Biochemical Assay Reagents
|
Metabolic Disease
|
|
Phospholipase A2, Honey bee venom (Apis mellifera) (EC 3.1.1.4) hydrolyzes the β-ester bond of zwitterionic glycerophospholipids. Preferred substrates are phosphatidylcholine, phosphatidylethanolamine, and their plasmalogen analogues.
|
-
- HY-116165
-
|
|
Phospholipase
|
Cancer
|
|
ML298 is a potent and selective inhibitor of Phospholipase D2 (PLD2) with an IC50 of 355 nM. ML298 decreases invasive migration in U87-MG glioblastoma cells .
|
-
- HY-124305
-
|
|
Endogenous Metabolite
|
Infection
|
|
ML395 is a potent and selective allosteric inhibitor of phospholipase D2 with antiviral activity. The cellular PLD1 IC50 value of ML395 exceeds 30,000 nM, while its cellular PLD2 IC50 value is 360 nM. ML395 shows excellent pharmacokinetic characteristics in vitro and physiochemical properties superior to other reported phospholipase inhibitors. ML395 shows interesting antiviral activity in cell-based assays against multiple influenza virus strains (H1, H3, H5, and H7) .
|
-
- HY-N7036
-
-
- HY-153561
-
|
|
Phospholipase
|
Neurological Disease
|
|
Lp-PLA2-IN-15 (example 2) is a lipoprotein-associated phospholipase A2 (Lp-PLA 2) inhibitor, which can be used in the research of Alzheimer's disease, etc .
|
-
- HY-153561A
-
|
|
Phospholipase
|
Neurological Disease
|
|
Lp-PLA2-IN-16 (example 1) is a lipoprotein-associated phospholipase A2 (Lp-PLA 2) inhibitor, which can be used in the research of Alzheimer's disease, etc .
|
-
- HY-W019838S
-
-
- HY-103097
-
|
|
Phospholipase
|
Others
|
|
ST271 is a potent inhibitor of protein tyrosine kinase (PTK), inhibits phospholipase D activation stimulated by fMet-Leu-Phe and PAF, with IC50s of 6.7 and 9 μM, respectively.
|
-
- HY-131181
-
LEI-401
2 Publications Verification
|
Phospholipase
|
Neurological Disease
|
|
LEI-401 is a first-in-class, selective, and CNS-active NAPE-PLD (N-acylphosphatidylethanolamine phospholipase D) inhibitor, with an IC50 of 27 nM. LEI-401 modulates emotional behavior in mice .
|
-
- HY-123202
-
|
|
P2Y Receptor
|
Cancer
|
|
MRS2603 is a pyridoxal derivative. MRS2603 antagonized both P2Y1 and P2Y13 receptors .
|
-
- HY-168765
-
|
LSN433771
|
Phospholipase
|
Cardiovascular Disease
|
|
LY433771 (LSN433771) (Compound 8) is a type X secretory phospholipase A2 (sPLA2) inhibitor with an IC50 value of 3 nM, which can be used in the study of cardiovascular diseases .
|
-
- HY-101015A
-
-
- HY-119093
-
-
- HY-126072
-
|
|
Drug Isomer
|
Others
|
|
(Rac)-GK563 is the isomer of GK563 (HY-138990). GK563 is a Ca 2+-independent group VI phospholipase A2 (GVIA iPLA2) inhibitor .
|
-
- HY-D1647
-
|
|
Phospholipase
|
Others
|
|
7-Hydroxycoumarinyl-γ-linolenate is a cytosolic phospholipase A2 (cPLA2) fluorogenic substrate. 7-Hydroxycoumarinyl-γ-linolenate can be used to monitor the enzymatic activity of cPLA2 .
|
-
- HY-123070
-
|
|
Phospholipase
|
Inflammation/Immunology
|
|
ONO-RS-082 is an inhibitor of phospholipase A (PLA) . ONO-RS-082 inhibits PLA2 with the IC50 of 1.0 μM, but does not inhibit PLC even at 100 μM .
|
-
- HY-172326
-
-
- HY-10801
-
|
|
Phospholipase
|
Inflammation/Immunology
|
|
CAY10650 is a highly potent cytosolic phospholipase A2α (cPLA2α) inhibitor with an IC50 value of 12 nM. CAY10650 suppresses lipid droplets formation and PGE2 secretion .
|
-
- HY-169114
-
|
|
5-HT Receptor
Phospholipase
|
Cardiovascular Disease
|
|
Goxalapladib is a 5-HT6 receptor modulator that blocks lipoprotein-associated phospholipase A2 (Lp-PLA2) activity. Goxalapladib is promising for research of atherosclerosis-associated cardiovascular diseases .
|
-
- HY-P2878B
-
|
|
Biochemical Assay Reagents
|
Metabolic Disease
|
|
Phosphodiesterase I, Bothrops atrox (EC 3.1.4.1) breaks phosphodiester bonds and catalyzes the hydrolysis of various nucleotide polyphosphates. Phosphodiesterase I is released from eucaryotic plasma membranes by phosphatidylinositol-specific phospholipase C.
|
-
- HY-100168
-
BAPTA
Maximum Cited Publications
36 Publications Verification
|
Phospholipase
|
Others
|
|
BAPTA is a selective and cell-impermeant chelator for calcium. BAPTA has high selectivity against magnesium and calcium. BAPTA can also inhibit phospholipase C activity independently of their role as Ca 2+ chelators .
|
-
- HY-128762
-
|
|
Phospholipase
|
Cancer
|
|
ML256 is a covalent lipoprotein-associated phospholipase A2 (Lp-PLA2 inhibitor. ML256 can be used for the study of neoplasms harboring a constitutively active variant of one or both of KRAS or HRAS .
|
-
- HY-U00037
-
|
PLA 725
|
Phospholipase
|
Inflammation/Immunology
|
|
Ecopladib is a sub-micromolar inhibitor of cytosolic phospholipase A2α (cPLA2α), with IC50s of 0.15 μM and 0.11 μM in the GLU micelle and rat whole blood assays, respectively.
|
-
- HY-17485
-
|
EB-382
|
Phospholipase
COX
|
Inflammation/Immunology
|
|
Alminoprofen (EB-382) is a nonsteroidal anti-inflammatory agent (NSAID) of the phenylpropionic acid class. Alminoprofen possesses a dual anti-inflammatory action, by inhibiting both secretory phospholipase A2 (sPLA2) and COX-2 .
|
-
- HY-108616
-
|
|
Phospholipase
|
Cancer
|
|
VU 0364739 hydrochloride is a highly selective phospholipase D2 (PLD2) inhibitor with IC50s of 20 and 1500 nM for PLD2 and PLD1, respectively. VU 0364739 hydrochloride induces apoptosis and it can be used for cancer research .
|
-
- HY-102004
-
|
SB 659032
|
Phospholipase
|
Neurological Disease
Inflammation/Immunology
|
|
Rilapladib (SB 659032) is a selective Lp-PLA2 (lipoprotein-associated phospholipase A2) inhibitor with an IC50 of 230 pM . Rilapladib (SB 659032) is also a PAFR (Platelet Activating Factor Receptor) antagonist .
|
-
- HY-116273
-
|
|
Phospholipase
|
Cancer
|
|
ML299 is a selective allosteric modulator and a dual inhibitor of phospholipases D1 and D2 (IC50 values are 6 and 12 nM, respectively). ML299 decreases invasive migration in U87-MG glioblastoma cells .
|
-
- HY-133149
-
|
|
Phospholipase
|
Cardiovascular Disease
|
|
Lp-PLA2-IN-3 is a potent and orally bioavailable lipoprotein-associated phospholipase A2 (Lp-PLA2) inhibitor, with an IC50 of 14 nM for recombinant human Lp-PLA2 (rhLpPLA2) .
|
-
- HY-P2878C
-
|
|
Biochemical Assay Reagents
|
Metabolic Disease
|
|
Phosphodiesterase I, Crotalus atrox (Western Diamondback Rattlesnake) (EC 3.1.4.1) breaks phosphodiester bonds and catalyzes the hydrolysis of various nucleotide polyphosphates. Phosphodiesterase I is released from eucaryotic plasma membranes by phosphatidylinositol-specific phospholipase C.
|
-
- HY-19757
-
-
- HY-100168A
-
|
|
Phospholipase
|
Others
|
|
BAPTA tetrasodium is a selective and cell-impermeant chelator for calcium. BAPTA tetrasodium has high selectivity against magnesium and calcium. BAPTA can also inhibit phospholipase C activity independently of their role as Ca 2+ chelators .
|
-
- HY-100168B
-
|
|
Phospholipase
|
Others
|
|
BAPTA tetrapotassium is a selective and cell-impermeant chelator for calcium. BAPTA has high selectivity against magnesium and calcium. BAPTA tetrapotassium can also inhibit phospholipase C activity independently of their role as Ca 2+ chelators .
|
-
- HY-108612A
-
|
CAY10593 hydrochloride
|
Phospholipase
|
Cancer
|
|
VU0155069 hydrochloride (CAY10593 hydrochloride) is a potent selective phospholipase D (PLD) inhibitor. The IC50 values for PLD1 and PLD2 are 46 and 933 nM, respectively. VU0155069 hydrochloride inhibits migration of human and mouse breast cancer cell lines .
|
-
- HY-W568087
-
|
|
Phospholipase
|
Others
|
|
5-Bromo-4-chloro-3-indoxyl myo-inositol-1-phosphate ammonium is a chromogenic substrate that can be used to detect the activity of phosphatidylinositol-specific phospholipase C (PI-PLC) .
|
-
- HY-108612
-
|
CAY10593
|
Phospholipase
|
Cancer
|
|
VU0155069 (CAY10593), is a selective phospholipase D1 (PLD1) inhibitor with an IC50 value of 46 nM in vitro. VU0155069 (CAY10593) strongly inhibits the invasive migration of several cancer cell lines in transwell assays .
|
-
- HY-W778574
-
|
|
Phospholipase
|
Cardiovascular Disease
Others
Neurological Disease
|
|
BAPTA tetracesium is a selective and cell-impermeant chelator for calcium. BAPTA tetracesium has high selectivity against magnesium and calcium. BAPTA tetracesium can also inhibit phospholipase C activity independently of their role as Ca 2+ chelators .
|
-
- HY-100045
-
|
4-Nitrophenylphosphorylcholine; 4-Nitrophenylphosphorylcholine; O-(4-Nitrophenylphosphoryl)choline
|
Endogenous Metabolite
|
Metabolic Disease
|
|
p-Nitrophenyl phosphorylcholine (4-Nitrophenylphosphorylcholine) is a chromogenic substrate that is used to measure phospholipase C (PLC) activity. Hydrolysis of p-nitrophenylphosphorylcholine by PLC results in the liberation of p-nitrophenol, which can be measured at 405 nm at pH 7.2-7.5.
|
-
- HY-111208
-
|
|
Phospholipase
|
Cancer
|
|
CCT129957 is an indole derivative and a potent phospholipase C-γ (PLC-γ) inhibitor with an IC50 of ~3 μM and a GC50 of 15 μM. CCT129957 inhibits Ca 2+ release in squamous carcinoma cells at ~15 μM .
|
-
- HY-117068
-
|
(R,E)-Bromoenol lactone
|
Phospholipase
|
Others
|
|
(R)-Bromoenol lactone ((R)-BEL) is an irreversible, chiral, mechanism-based inhibitor of calcium-independent phospholipase γ (iPLA2γ). (R)-BEL inhibits human recombinant iPLA2γ with an IC50 of approximately 0.6 µM .
|
-
- HY-125254
-
LEI110
1 Publications Verification
|
Phospholipase
HRASLS
|
Infection
Metabolic Disease
|
|
LEI110 is a potent, selective and cell-permeable pan-inhibitor of the HRASLS family of thiol hydrolases. LEI110 inhibits PLA2G16, HRASLS2, RARRES3 and iNAT, with pIC50 values of 7.0, 6.8, 6.8, and 7.6, respectively. LEI110 reduces cellular arachidonic acid levels and oleic acid-induced lipolysis in HepG2 cells .
|
-
- HY-N1450R
-
|
|
Reference Standards
Phospholipase
|
Cancer
|
|
Aristolochic acid C (Standard) is the analytical standard of Aristolochic acid C. This product is intended for research and analytical applications. Aristolochic acid C is a derivative of Aristolochic acid. Aristolochic acid is a phospholipase A2 (PLA2) inhibitor, which disrupts cortical microtubule arrays and root growth in Arabidopsis .
|
-
- HY-173587
-
|
1,2-Bis(heptanoylthio) glycerophosphatidylglycerol sodium
|
Phospholipase
|
Metabolic Disease
|
|
1,2-Bis(heptanoylthio)-sn-glycero-3-PG (1,2-Bis(heptanoylthio) glycerophosphatidylglycerol) sodium is a fatty acylthioesterified phosphatidylglycerol derivative that can be used to mimic the action of phospholipases or as a probe molecule for membrane fusion studies .
|
-
- HY-17569R
-
|
|
Reference Standards
Phospholipase
|
Inflammation/Immunology
|
|
Difluprednate (Standard) is the analytical standard of Difluprednate. This product is intended for research and analytical applications. Difluprednate is a topical corticosteroid, which is thought to act by the induction of phospholipase A2 inhibitory proteins (lipocortins). Difluprednate is used for the symptomatic treatment of inflammation and pain associated with ocular surgery.
|
-
- HY-12598AR
-
|
(RS)-3,5-DHPG (Standard)
|
mGluR
Reference Standards
|
Neurological Disease
|
|
DHPG (Standard) is the analytical standard of DHPG. This product is intended for research and analytical applications. DHPG is the agonist for mGluR 1/5 (EC50 for mGluR 1 is 60 nM) that activates the phospholipase C (PLC) pathway, and leads ultimately to the activation of protein kinase C (PKC) .
|
-
- HY-P1341
-
|
Orexin A (17-33) (human, mouse, rat, bovine)
|
Orexin Receptor (OX Receptor)
Sigma Receptor
Phospholipase
|
Neurological Disease
|
|
OXA (17-33) (Orexin A (17-33) (human, mouse, rat, bovine)) is the shortest active orexin peptide that selectively targets OX1 (EC50=8.29 nM), with 23-fold selectivity for the OX1 receptor over the OX2 receptor. The activity of OXA (17-33) depends on the Tyr17, Leu20, Asn25, His26 residues and the spatial conformation of the α-helix. OXA (17-33) activates signaling pathways involving inositol-1,4,5-trisphosphate receptor (IP3R), phospholipase D (PL-D) and choline-Sigma-1R, thereby increasing the cytoplasmic Ca 2+ level in nucleus accumbens neurons, an effect that is blocked by Sigma-1R antagonists. OXA (17-33) serves as an important biological probe for investigating the function of the OX1 receptor. OXA (17-33) can be modified via incorporation of mixed disulfide bonds of homocysteine and cysteamine, and is widely used in studies related to insomnia and narcolepsy .
|
-
- HY-133233
-
|
1-Palmitylthio-2-palmitoylamido-1,2-dideoxy-sn-glycero-3-phosphorylcholine
|
Endogenous Metabolite
Phospholipase
|
Metabolic Disease
|
|
Thioetheramide-PC (1-Palmitylthio-2-palmitoylamido-1,2-dideoxy-sn-glycero-3-phosphorylcholine) is a structurally modified phospholipid that acts as a competitive, reversible inhibitor of secretory phospholipase A2 (sPLA2). Thioetheramide-PC has an IC50 value of 2 μM at a substrate concentration of 0.5 mM. In addition to binding to the catalytic site of sPLA2, Thioetheramide-PC also binds to the activation site of the enzyme. Thioetheramide-PC binds more tightly to the activation site than to the catalytic site. As a result of this dual interaction, at low concentrations, Thioetheramide-PC may activate phospholipase activity rather than inhibit it.
|
-
- HY-182452
-
|
|
Phosphodiesterase (PDE)
Phospholipase
|
Cardiovascular Disease
|
|
U 84569 is a potent low-Km cAMP-dependent Phosphodiesterase inhibitor, with an IC50 value of 300 nM in platelet cytosol. By inhibiting phosphodiesterase and elevating cAMP levels, U 84569 indirectly blocks receptor-mediated Phospholipase C activation, thereby inhibiting platelet aggregation .
|
-
- HY-101579
-
|
|
COX
Lipoxygenase
Phospholipase
|
Inflammation/Immunology
|
|
LY 178002 is a potent inhibitor of 5-lipoxygenase (5-LPO), phospholipase A2, with IC50 of 0.6 μM for 5-lipoxygenase, inhibits cellular production of LTB4 by human polymorphonuclear leukocytes, and shows relatively weak inhibition on cyclooxygenase.
|
-
- HY-103411
-
|
|
Dopamine Receptor
|
Neurological Disease
|
|
SKF83822 hydrobromide is a potent dopamine D1 receptor agonist. SKF83822 hydrobromide activates Gs/olf/adenylyl cyclase (AC)-coupled D1 receptors, but not phospholipase C (PLC)-coupled D1-like receptors .
|
-
- HY-W339757
-
|
|
mTOR
Endogenous Metabolite
|
Cancer
|
|
Dioctanoylphosphatidic acid sodium functions as a modulator of phagocyte respiratory burst, acts as a precursor to diacylglycerol and lysophosphatidic acid, and influences the phosphorylation of the mammalian target of rapamycin (mTOR) while enhancing the viability of gallbladder carcinoma cells treated with histone deacetylase inhibitors (HDACIs); it is derived from glycerophospholipid through the action of phospholipase D.
|
-
- HY-116874
-
|
|
Dopamine Receptor
|
Neurological Disease
|
|
SKF 83822 is an atypical agonist of dopamine D1 receptor. SKF 83822 activates adenylyl cyclase (AC), but not phospholipase C (PLC). SKF 83822 is also proved to stimulate AC via cAMP production. SKF 83822 can be used for research of schizophrenia .
|
-
- HY-165327
-
|
|
Phospholipase
|
Inflammation/Immunology
|
|
AGN-190383 is a bee venom phospholipase A2 inhibitor. AGN 190383 inhibits both hormone-operated and depolarization-dependent calcium mobilization as well as fMLP stimulated increases in free cytosolic calcium. AGN-190383 has anti-inflammatory activity .
|
-
- HY-N7036R
-
-
- HY-113507
-
-
- HY-100287
-
|
|
Prostaglandin Receptor
Phospholipase
|
Endocrinology
|
|
2-(E-2-decenoylamino)ethyl 2-(cyclohexylethyl) sulfide is a compound that inhibits stress-induced ulcer and low toxicity, and can maintain the content of phospholipase A2 and prostaglandin E2 in ulcerated rats induced by water immersed restrained stress.
|
-
- HY-115768
-
|
Poly-p-methoxyphenethylmethylamine
|
Phospholipase
|
Neurological Disease
Cancer
|
|
Compound 48/80 (Poly-p-methoxyphenethylmethylamine) is widely used in animal and tissue models as a "selective" mast cell activator. Compound 48/80 acts at the mast cell membrane to stimulate trimeric G-proteins and induces degranulation via phospholipase C and D pathways .
|
-
- HY-W012595AR
-
|
trans-Benzalacetone (Standard)
|
Reference Standards
Phospholipase
|
Inflammation/Immunology
|
|
trans-Benzylideneacetone (Standard) is the analytical standard of trans-Benzylideneacetone. This product is intended for research and analytical applications. trans-Benzylideneacetone (trans-Benzalacetone), a metabolite of gram-negative entomopathogenic bacterium Xenorhabdus nematophila, is an enzyme inhibitor against phospholipase A2 (PLA2). trans-Benzylideneacetone is an immunosuppressant[1].
|
-
- HY-11059
-
|
|
Phospholipase
|
Inflammation/Immunology
|
|
KH064, a D-tyrosine derivative, is an orally active, potent secretory phospholipase A2 (sPLA2) inhibitor with an IC50 of 29 nM for human nonpancreatic secretory PLA2 isoform IIa (hnpsPLA2-IIa). KH064 has anti-inflammatory activity .
|
-
- HY-119093R
-
|
|
Phospholipase
Dopamine Receptor
|
Neurological Disease
Cancer
|
|
Halopemide (Standard) is the analytical standard of Halopemide. This product is intended for research and analytical applications. Halopemide is a potent phospholipase D (PLD) inhibitor, with IC50s of 220 and 310 nM for human PLD1 and PLD2, respectively. Halopemid is a dopamine receptors antagonist, and acts a psychotropic agent .
|
-
- HY-156041
-
|
Lyso-PE (egg); LPE (egg); L-α-lysophosphatidylethanolamine
|
Endogenous Metabolite
|
Metabolic Disease
|
|
Lysophosphatidylethanolamine (LPE) is a naturally-occurring lysophospholipid that can be generated via deacylation of phosphatidylethanolamine by phospholipase A2 (PLA2). It increases the phosphorylation of ERK1/2 in PC12 cells, an effect that can be blocked by the MEK inhibitors U-0126 (HY-12031A) and PD 98059 (HY-12028) and the EGFR inhibitor AG-1478 (HY-13524).1 LPE also increases neurite outgrowth and expression of neurofilament M in PC12 cells. LPE inhibits the activity of phospholipase D (PLD) partially purified from cabbage.3 This product contains lysophosphatidylethanolamine molecular species with variable fatty acyl chain lengths at the sn-1 position and a hydroxy group at the sn-2 position.
|
-
- HY-158792
-
|
|
Others
|
Others
|
|
GK241 (compound 31a-c) is a 2-oxoamide-based compound that has inhibitory activity against human and mouse group IIA secretory phospholipase A2 (GIIA sPLA2) (IC50 of 143 nM and 68 nM, respectively), and its inhibitory mechanism was studied by molecular dynamics simulation.
|
-
- HY-W012595
-
-
- HY-120986
-
|
(S)-BEL; (S,E)-Bromoenol lactone
|
Phospholipase
|
Inflammation/Immunology
|
|
(S)-Bromoenol lactone ((S)-BEL) is an irreversible, chiral, mechanism-based inhibitor of calcium-independent phospholipase A2β (iPLA2β) that inhibits the vasopressin-induced release of arachidonate from cultured rat aortic smooth muscle (A10) cells with an IC50 of 2 µM .
|
-
- HY-N16481
-
|
|
COX
Phospholipase
|
Inflammation/Immunology
|
|
Parameritannin A-1 is a tetrameric proanthocyanidin (PAC) that can be isolated from the bark of Parameria laevigata Moldenke (Apocynaceae). Parameritannin A-1 is a COX-2 inhibitor. Parameritannin A-1 also inhibits the activity of phospholipase A2 (PLA2) .
|
-
- HY-17485R
-
|
EB-382 (Standard)
|
Reference Standards
Phospholipase
COX
|
Inflammation/Immunology
|
|
Alminoprofen (Standard) is the analytical standard of Alminoprofen. This product is intended for research and analytical applications. Alminoprofen (EB-382) is a nonsteroidal anti-inflammatory agent (NSAID) of the phenylpropionic acid class. Alminoprofen possesses a dual anti-inflammatory action, by inhibiting both secretory phospholipase A2 (sPLA2) and COX-2 .
|
-
- HY-130592
-
|
C48/80 trihydrochloride
|
Phospholipase
|
Neurological Disease
|
|
Compound 48/80 trihydrochloride (C48/80 trihydrochloride) is a mixture of condensation products of N-methyl-p-methoxyphenethylamine with formaldehyde. Compound 48/80 trihydrochloride is also a histamine releaser and a mast cell degranulator. Compound 48/80 inhibits phosphatidylinositol-specific phospholipase C activity from human platelets .
|
-
- HY-103097R
-
|
|
Reference Standards
Phospholipase
|
Others
|
|
ST271 (Standard) is the analytical standard of ST271 (HY-103097). This product is intended for research and analytical applications. ST271 is a potent inhibitor of protein tyrosine kinase (PTK), inhibits phospholipase D activation stimulated by fMet-Leu-Phe and PAF, with IC50s of 6.7 and 9 μM, respectively.
|
-
- HY-114095
-
-
- HY-178123
-
|
|
Others
|
Inflammation/Immunology
|
|
BAY-439 is a human Group V Phospholipase A2 (hPLA2-G5) inhibitor. BAY-439 can be used as a chemical probe for investigating hPLA2-G5-mediated inflammatory-related diseases, especially inflammatory pain.
|
-
- HY-101015
-
|
|
Phospholipase
Apoptosis
|
Inflammation/Immunology
|
|
(2E)-OBAA is a potent phospholipase A2 (PLA2) inhibitor, with an IC50 of 70 nM. (2E)-OBAA induces apoptosis of HUVEC cells. (2E)-OBAA blocks Melittin-induced Ca 2+ influx in Trypanosoma brucei, with an IC50 of 0.4 μM .
|
-
- HY-N2330
-
|
|
Lipase
|
Metabolic Disease
|
|
Lipstatin is a pancreatic lipase inhibitor (IC50=0.14 μM), whose structure is closely related to the known inhibitor, Esterastin. Lipstatin inhibits the absorption of triglycerides without affecting the absorption of oleic acid. Lipstatin has no inhibitory effects on other pancreatic enzymes, such as phospholipase A2 and trypsin (<200 μM) .
|
-
- HY-W654264
-
|
|
Endogenous Metabolite
Integrin
|
Cardiovascular Disease
|
|
2-Methylbutyrylcarnitine (chloride) is a gut microbial metabolite which binds to integrin α2β1 in platelets, potentiating cytosolic phospholipase A2 (cPLA2) activation and platelet hyperresponsiveness. 2-Methylbutyrylcarnitine (chloride) enhances platelet hyperreactivity and thrombus formation in mice. 2-Methylbutyrylcarnitine (chloride) is a branched-chain acylcarnitine .
|
-
- HY-107411
-
|
(6E)-Bromoenol lactone
|
Phospholipase
|
Inflammation/Immunology
|
|
Bromoenol lactone ((6E)-Bromoenol lactone) is a suicide-based irreversible, selective, potent inhibitor of calcium-independent phospholipase A2 (iPLA2β) with an IC50 value of approximately 7 μM, which inhibits antigen-stimulated mast cell exocytosis without blocking Ca 2+ influx .
|
-
- HY-10801R
-
|
|
Reference Standards
Phospholipase
|
Inflammation/Immunology
|
|
CAY10650 (Standard) is the analytical standard of CAY10650 (HY-10801). This product is intended for research and analytical applications. CAY10650 is a highly potent cytosolic phospholipase A2α (cPLA2α) inhibitor with an IC50 value of 12 nM. CAY10650 suppresses lipid droplets formation and PGE2 secretion .
|
-
- HY-102004R
-
|
SB 659032 (Standard)
|
Reference Standards
Phospholipase
|
Neurological Disease
Inflammation/Immunology
|
|
Rilapladib (Standard) is the analytical standard of Rilapladib (HY-102004). This product is intended for research and analytical applications. Rilapladib (SB 659032) is a selective Lp-PLA2 (lipoprotein-associated phospholipase A2) inhibitor with an IC50 of 230 pM . Rilapladib (SB 659032) is also a PAFR (Platelet Activating Factor Receptor) antagonist .
|
-
- HY-118628
-
|
N-(p-Amylcinnamoyl) anthranilic acid; ACA
|
Phospholipase
TRP Channel
|
Cardiovascular Disease
|
|
(E/Z)-BML264 (N-(p-amylcinnamoyl) Anthranilic Acid) is a broad spectrum Phospholipase A2 (PLA2) inhibitor and TRP channel blocker . (E/Z)-BML264 (N-(p-amylcinnamoyl) Anthranilic Acid) is also an effective reversible inhibitor of calcium-activated chloride channels, has potential to treat arrhythmia .
|
-
- HY-112605
-
|
|
Phospholipase
|
Cardiovascular Disease
|
|
sPLA2-X Inhibitor 31 is a selective secreted phospholipase A2 type X (sPLA2-X) inhibitor with IC50s of 26 nM, 310 nM, and 2230 nM for sPLA2-X, sPLA2-IIa, and sPLA2-V, respectively .
|
-
- HY-173335
-
|
|
Phospholipase
|
Infection
|
|
PLA2-IN-1 (Compound 7) is a potent and selective inhibitor of phospholipase A2 (PLA2) with an IC50 value of 1 nM PLA2-IN-1 inhibits PLA2-induced coagulopathy in vitro. PLA2-IN-1 is promising for research of snakebite envenomation caused by cobra venom .
|
-
- HY-108630
-
|
|
Phospholipase
|
Others
|
|
U-73343, works as a protonophore, is an inactive analog of U-73122 and can be used as a negative control. U-73343 dose-dependently inhibits acid secretion irrespective of the stimulant. U-73122 is a phospholipase C (PLC) and 5-LO (5-lipoxygenase) inhibitor with an IC50 of 1-2.1 μM for PLC .
|
-
- HY-176008
-
|
|
Drug Derivative
|
Inflammation/Immunology
|
|
Lauric acid leelamide is the lauric acid (C-12) amide analog of Leelamine (HY-W005629). Leelamine exhibits inhibitory activity against pyruvate dehydrogenase kinase (PDHK) with an IC50 value of 9.5 µM. Leelamine derivatives possess anti-inflammatory effects and can inhibit phospholipase A2 activity from various sources .
|
-
- HY-W012595R
-
|
Benzalacetone (Standard)
|
Reference Standards
Endogenous Metabolite
Antibiotic
Bacterial
Tyrosinase
Phospholipase
|
Infection
Metabolic Disease
Inflammation/Immunology
|
|
Benzylideneacetone (Standard) is the analytical standard of Benzylideneacetone. This product is intended for research and analytical applications. Benzylideneacetone (Benzalacetone) is an orally active antibiotic, tyrosinase inhibitor, phospholipase A2 inhibitor, and immunosuppressant. Benzylideneacetone has antibacterial activity against some gram-negative plant-pathogenic bacteria. Benzylideneacetone can also be used in the synthesis of chemicals and drugs, and as a flavoring additive for some foods .
|
-
- HY-115403
-
FKGK18
1 Publications Verification
|
Phospholipase
Apoptosis
|
Metabolic Disease
|
|
FKGK18 is a selective group VIA calcium-independent phospholipase A2 (GVIA iPLA2) inhibitor. FKGK18 is a fluoroketone (FK)-based compound with IC50s of 50 nM and 3 μM for iPLA2β and iPLA2γ. FKGK18 can be used for the research of beta-cell apoptosis and diabetes .
|
-
- HY-172325
-
|
|
Biochemical Assay Reagents
|
Others
|
|
DPPI-5-P (ammonium) (PtdIns-(5)-P1) can be phosphorylated to form disphosphates such as PtdIns-(4,5)-P2. DPPI-5-P (ammonium) can also be cleaved by PI-specific phospholipase C (PLC) to give inositol triphosphates .
|
-
- HY-13402A
-
|
LY315920 sodium
|
Phospholipase
|
Inflammation/Immunology
|
|
Varespladib sodium (LY315920 sodium) is a potent and selective group IIA, secretory phospholipase A2 (sPLA2) inhibitor with an IC50 of 9 nM. Varespladib sodium exhibits the significant inhibitory effect on sPLA2 activity in serum from various species including rat, rabbit, guinea pig and human with IC50s of 8.1 nM, 5.0 nM, 3.2 nM and 6.2 nM, respectively .
|
-
- HY-12807A
-
|
5-Fluoro-2-indolyl deschlorohalopemide hydrochloride
|
Phospholipase
|
Cardiovascular Disease
Neurological Disease
Inflammation/Immunology
Cancer
|
|
FIPI hydrochloride is a phospholipase D (PLD) inhibitor with an IC50 for PLD1 and PLD2 of about 25 nM. FIPI hydrochloride regulates cytoskeletal recombination, cell diffusion and chemotaxis. FIPI hydrochloride can be used in cancer research. In addition, FIPI hydrochloride can enhance the secretion and aggregation of platelet dense particles, inhibit thrombosis, reduce ischemic stroke infarct volume and improve nerve function .
|
-
- HY-177218
-
|
NSC 119910
|
Phospholipase
Opioid Receptor
|
Neurological Disease
|
|
M119 (NSC 119910) is a selective Gβγ-subunit inhibitor. M119 selectively potentiates μ-opioid-dependent antinociception. M119 inhibits μ-receptor-dependent phospholipase (PLC) activation. M119 can enhance opioid analgesia and attenuate its acute tolerance and dependence in mice. M119 can be used for pain research .
|
-
- HY-13402
-
|
LY315920
|
Phospholipase
|
Inflammation/Immunology
|
|
Varespladib (LY315920) is a potent and selective group IIA, secretory phospholipase A2 (sPLA2) inhibitor with an IC50 of 9 nM. Varespladib exhibits the significant inhibitory effect on sPLA2 activity in serum from various species including rat, rabbit, guinea pig and human with IC50s of 8.1 nM, 5.0 nM, 3.2 nM and 6.2 nM, respectively .
|
-
- HY-108612R
-
|
CAY10593 (Standard)
|
Reference Standards
Phospholipase
|
Cancer
|
|
VU0155069 (Standard) is the analytical standard of VU0155069 (HY-108612). This product is intended for research and analytical applications. VU0155069 (CAY10593), is a selective phospholipase D1 (PLD1) inhibitor with an IC50 value of 46 nM in vitro. VU0155069 (CAY10593) strongly inhibits the invasive migration of several cancer cell lines in transwell assays .
|
-
- HY-12807
-
FIPI
5 Publications Verification
5-Fluoro-2-indolyl deschlorohalopemide
|
Phospholipase
|
Cardiovascular Disease
Neurological Disease
Inflammation/Immunology
Cancer
|
|
FIPI is a phospholipase D (PLD) inhibitor with an IC50 for PLD1 and PLD2 of about 25 nM. FIPI regulates cytoskeletal recombination, cell diffusion and chemotaxis. FIPI can be used in cancer research. In addition, FIPI can enhance the secretion and aggregation of platelet dense particles, inhibit thrombosis, reduce ischemic stroke infarct volume and improve nerve function .
|
-
- HY-125986
-
|
|
Phospholipase
|
Neurological Disease
|
GK187 is a potent and selective Group VIA calcium-independent phospholipase A2 (GVIA iPLA2) inhibitor with an XI(50) value of 0.0001. GK187 can be used for researching various neurological disorders .
[The XI(50) is the mole fraction of the inhibitor in the total substrate interface required to inhibit the enzyme by 50%.]
|
-
- HY-163959
-
|
|
PNPLA3
|
Metabolic Disease
Cancer
|
|
PF-07853578 is an orally active PNPLA3 modulator. PF-07853578 significantly reduces human PNPLA3-I148M protein levels and effectively decreases hepatic triglyceride content by reducing this mutant protein. PNPLA3 degrader-1 can be used in the research of liver cirrhosis and hepatocellular carcinoma .
|
-
- HY-169254
-
|
|
Phospholipase
|
Metabolic Disease
|
|
sPLA2 inhibitor 2 (compound 6a) is a sPLA2 inhibitor, with IC50 of 0.0475 μM. sPLA2 inhibitor 2 can be used in diabetes research .
|
-
- HY-101293
-
-
- HY-120621
-
|
|
Phospholipase
|
Inflammation/Immunology
|
|
BMS-229724 is an orally active and tight-binding cytosolic phospholipase A2 (cPLA2) inhibitor with an IC50 of 2.8 μM. BMS-229724 can inhibit the production of arachidonic acid and eicosanoids in U937 cells, neutrophils, platelets, and other cells. BMS-229724 has anti-inflammatory activity and can be used in the research of diseases such as skin inflammation .
|
-
- HY-153213A
-
|
|
TSH Receptor
|
Endocrinology
|
|
Org 274178-0 is a selective thyroid-stimulating hormone receptor (TSHR) antagonist with a pIC50 value for TSHR is 5.03. Org 274178-0 inhibits the activation of cAMP signaling pathway and phospholipase C (PLC) signaling pathway mediated by thyroid-stimulating hormone (TSH) and TSH receptor-stimulating immunoglobulins (TSIs). Org 274178-0 is promising for research of Graves’ disease and Graves’ ophthalmopathy .
|
-
- HY-W713925
-
|
|
Endogenous Metabolite
|
Metabolic Disease
|
|
Diheptanoyl Thio-PC is a substrate for all phospholipase A2s (PLA2s) with the exception of cPLA2 and PAF-acetyl hydrolase (PAF-AH).1 Interaction of this compound with a PLA2 results in cleavage of the sn-2 fatty acid generating a free thiol on the lysophospholipid. This free thiol can be detected using chromogenic substrates such as DTNB (Ellman’s reagent) and DTP.
|
-
- HY-150135B
-
|
Inositol 1,4,5-trisphosphate tripotassium; Ins(1,4,5)-P3 tripotassium
|
Calcium Channel
|
Neurological Disease
|
|
D-myo-Inositol 1,4,5-trisphosphate tripotassium, a second messenger, elicits Ca 2+ mobilization. D-myo-Inositol 1,4,5-trisphosphate tripotassium inhibits the binding of phosphoinositide-specific phospholipase C-delta 1 (PLC-delta 1) to bilayer membranes composed of phosphatidylcholine (PC) and phosphatidylinositol 4,5-bisphosphate (PIP2) .
|
-
- HY-W329357
-
|
|
Endogenous Metabolite
|
Cardiovascular Disease
|
|
15:0 Lyso PC is a lysophosphatidylcholine (Lyso PC), a product of phospholipase A2 (PLA2) hydrolysis of phosphatidylcholine (PC) and is involved in cell membrane remodeling and inflammatory signaling. 15:0 Lyso PC demonstrates significant lipid metabolism disturbances in the serum with ischemic heart disease (IHD) and ischemic cardiomyopathy (ICM). 15:0 Lyso PC can be used as a lipid biomarker for cardiovascular disease .
|
-
- HY-127110
-
|
|
Phospholipase
|
Others
Neurological Disease
Inflammation/Immunology
|
|
AK106-001616 is a potent and selective inhibitor of cytosolic phospholipase A2 (cPLA2) (IC50=3.8 nmol/L). AK106-001616 is able to reduce the production of prostaglandins (PG) E2 and leukotrienes (LT) B4 by stimulated cells. AK106-001616 can be used in the study of inflammatory diseases, neuropathic pain and pulmonary fibrosis .
|
-
- HY-137677
-
|
Guanosine 5'-[γ-thio]triphosphate
|
GLUT
|
Metabolic Disease
|
|
GTPγS (Guanosine 5'-[γ-thio]triphosphate) is a G-protein activator that protects proteins from proteolytic degradation, stimulates GLUT4 translocation in a tyrosine kinase-dependent manner, stimulate phospholipases and induce actin polymerization. GTPγS to couple with G- protein α, to study its effect on kinase activity. GTPγS acts as a component of lysis buffer .
|
-
- HY-175982
-
|
|
Aurora Kinase
|
Cancer
|
|
AURKA-IN-3 (Compound AL8) is an irreversible covalent Aurora kinase A (AURKA) inhibitor with an IC50 value of 23.0 nM. AURKA-IN-3 inhibits the activation of cAMP signaling pathway and phospholipase C (PLC) signaling pathway mediated by AURKA, and reduces the autophosphorylation level of AURKA. AURKA-IN-3 is promising for research of malignant tumors associated with high AURKA expression (e.g., leukemia, lymphoma) .
|
-
- HY-117068S
-
|
(R,E)-Bromoenol lactone-d7
|
Isotope-Labeled Compounds
Phospholipase
|
Others
|
|
(R)-Bromoenol lactone-d7 ((R,E)-Bromoenol lactone-d7) is deuterium labeled (R)-Bromoenol lactone. (R)-Bromoenol lactone ((R)-BEL) is an irreversible, chiral, mechanism-based inhibitor of calcium-independent phospholipase γ (iPLA2γ). (R)-BEL inhibits human recombinant iPLA2γ with an IC50 of approximately 0.6 μM .
|
-
- HY-134082A
-
|
|
Phospholipase
|
Inflammation/Immunology
|
|
(Z)-Oleyloxyethyl phosphorylcholine ((Z)-OPC) is an isomer of Oleyloxyethyl phosphorylcholine (OPC). Oleyloxyethyl phosphorylcholine is an inhibitor of secreted Phospholipase A2 (sPLA2), which is involved in the biosynthesis of proinflammatory lipid media. Oleyloxyethyl phosphorylcholine can be used to study inflammatory diseases. Oleyloxyethyl phosphorylcholine also modified the red blood membrane and was used to bind the oxygen-carrying liquid perfluorocarbons as an antivenom agent to reduce toxin-induced hemolysis .
|
-
- HY-137677B
-
|
Guanosine 5'-[γ-thio]triphosphate tetralithium
|
GLUT
|
Metabolic Disease
|
|
GTPγS (Guanosine 5'-[γ-thio]triphosphate) tetralithium is a G-protein activator that protects proteins from proteolytic degradation, stimulates GLUT4 translocation in a tyrosine kinase-dependent manner, stimulate phospholipases and induce actin polymerization. GTPγS tetralithium to couple with G- protein α, to study its effect on kinase activity. GTPγS tetralithium acts as a component of lysis buffer .
|
-
- HY-138990
-
|
|
Phospholipase
Apoptosis
|
Inflammation/Immunology
|
|
GK563 is a selective Ca 2+-independent phospholipase A2 (GVIA iPLA2) inhibitor with an IC50 value of 1 nM. GK563 is 22000 times more active against GVIA iPLA2 than GIVA cPLA2. GK563 reduces β-cell apoptosis induced by proinflammatory cytokines, raising the possibility that it can be beneficial in countering autoimmune diseases, such as type 1 diabetes .
|
-
- HY-107416R
-
|
U-57908 (Standard)
|
DAGL
Reference Standards
Acyltransferase
mAChR
COX
Phospholipase
|
Neurological Disease
Metabolic Disease
|
|
RHC 80267 (Standard) is the analytical standard of RHC 80267 (HY-107416). This product is intended for research and analytical applications. RHC 80267 (U-57908) is a potent and selective inhibitor of diacylglycerol lipase (DAGL) (with IC50 of 4 μM in canine platelets). RHC-80267 inhibits cholinesterase activity with an IC50 of 4 μM, thereby enhancing the relaxation evoked by acetylcholine. RHC 80267 also inhibits COX and the hydrolysis of phosphatidylcholine (PC) .
|
-
- HY-107416
-
|
U-57908
|
DAGL
Acyltransferase
mAChR
COX
Phospholipase
|
Neurological Disease
Metabolic Disease
|
|
RHC 80267 (U-57908) is a potent and selective inhibitor of diacylglycerol lipase (DAGL) (with IC50 of 4 μM in canine platelets). RHC-80267 inhibits cholinesterase activity with an IC50 of 4 μM, thereby enhancing the relaxation evoked by acetylcholine. RHC 80267 also inhibits COX and the hydrolysis of phosphatidylcholine (PC) .
|
-
- HY-131688R
-
|
|
PARP
Caspase
Reference Standards
|
Inflammation/Immunology
|
|
Neomycin (sulfate) (Standard) is the analytical standard of Neomycin (sulfate). This product is intended for research and analytical applications. Neomycin sulfate, an aminoglycoside antibiotic, exerts antibacterial activity through irreversible binding of the nuclear 30S ribosomal subunit, thereby blocking bacterial protein synthesis. Neomycin sulfate is a known phospholipase C (PLC) inhibitor. Neomycin sulfate potently inhibits both nuclear translocation of angiogenin and angiogenin-induced cell proliferation and angiogenesis .
|
-
- HY-19619
-
|
|
Phospholipase
Apoptosis
|
Cancer
|
|
m-3M3FBS is a potent phospholipase C (PLC) activator. m-3M3FBS stimulates superoxide generation in human neutrophils, upregulates intracellular calcium concentration, and stimulates inositol phosphate generation in various cell lines. m-3M3FBS induces monocytic leukemia cell apoptosis .
|
-
- HY-P3906
-
|
|
Fungal
Apoptosis
Phospholipase
Reactive Oxygen Species (ROS)
|
Infection
|
|
Melittin free acid is a basic 26-amino-acid polypeptide, the major active ingredient of honeybee venom. Melittin free acid is an activator of phospholipase A2 (PLA2). Melittin free acid has broad-spectrum antifungal activity with MIC values of 0.4-60 μM. Melittin free acid hinders fungal growth by inducing cell apoptosis, repressing (1,3)-β-D-glucan synthase and participating in other pathways .
|
-
- HY-B0470R
-
|
|
Reference Standards
Bacterial
Antibiotic
Phospholipase
|
Infection
Cancer
|
|
Neomycin (sulfate) (Standard) is the analytical standard of Neomycin (sulfate). This product is intended for research and analytical applications. Neomycin sulfate, an aminoglycoside antibiotic, exerts antibacterial activity through irreversible binding of the nuclear 30S ribosomal subunit, thereby blocking bacterial protein synthesis. Neomycin sulfate is a known phospholipase C (PLC) inhibitor. Neomycin sulfate potently inhibits both nuclear translocation of angiogenin and angiogenin-induced cell proliferation and angiogenesis .
|
-
- HY-N7327
-
|
|
Phospholipase
|
Inflammation/Immunology
|
|
Ochnaflavone is an inhibitor of IIA-type secretory phospholipase A2 (sPLA2-IIA) with an IC50 of 3.45 µM. Ochnaflavone exhibits significant anti-inflammatory and liver-protective effects, capable of inhibiting the degradation of phosphatidylethanolamine (PE) and lipid peroxidation induced by carbon tetrachloride (CCl4) in rat liver, with an IC50 of 7.16 µM for lipid peroxidation. Ochnaflavone can be used in research on liver damage and inflammatory diseases .
|
-
- HY-13402AR
-
|
LY315920 sodium (Standard)
|
Phospholipase
Reference Standards
|
Inflammation/Immunology
|
|
Varespladib (sodium) (Standard) is the analytical standard of Varespladib (sodium). This product is intended for research and analytical applications. Varespladib sodium (LY315920 sodium) is a potent and selective group IIA, secretory phospholipase A2 (sPLA2) inhibitor with an IC50 of 9 nM. Varespladib sodium exhibits the significant inhibitory effect on sPLA2 activity in serum from various species including rat, rabbit, guinea pig and human with IC50s of 8.1 nM, 5.0 nM, 3.2 nM and 6.2 nM, respectively .
|
-
- HY-114873
-
|
LY25684
|
Phospholipase
COX
Lipoxygenase
Leukotriene Receptor
|
Inflammation/Immunology
|
|
LY256548 (LY25648) is an orally available anti-ischemic and anti-inflammatory compound with central nervous system activity. LY256548 is an inhibitor of phospholipase A2, 5-lipoxygenase (5-LOX), and COX, and inhibits A23187 (HY-N6687)-stimulated leukotriene B4 production. LY256548 inhibits bone damage and paw swelling in the rat Freund's complete adjuvant-induced arthritis (FCA) model .
|
-
- HY-13402R
-
|
LY315920 (Standard)
|
Phospholipase
Reference Standards
|
Inflammation/Immunology
|
|
Varespladib (Standard) is the analytical standard of Varespladib. This product is intended for research and analytical applications. Varespladib (LY315920) is a potent and selective group IIA, secretory phospholipase A2 (sPLA2) inhibitor with an IC50 of 9 nM. Varespladib exhibits the significant inhibitory effect on sPLA2 activity in serum from various species including rat, rabbit, guinea pig and human with IC50s of 8.1 nM, 5.0 nM, 3.2 nM and 6.2 nM, respectively .
|
-
- HY-E70632
-
|
|
Biochemical Assay Reagents
|
Neurological Disease
|
|
PIP5K1B participates in the biosynthesis of PI(4,5)P2. PIP5K1B is at the crossroad of different signaling pathways, mediating RAC1-dependent reorganization of actin filaments and contributing to the activation of phospholipase D2. PIP5K1B Recombinant Human Active Lipid Kinase can be used for the study of Friedreich’s ataxia (FRDA) .
|
-
- HY-W127380
-
|
|
Biochemical Assay Reagents
|
Others
|
|
Arachidonoyl Thio-PC is a substrate of many phospholipase A2 (PLA2), including sPLA2, cPLA2 and iPLA2. Cleavage of sn-2 fatty acids by PLA2 results in the production of free thiols, which react with chromogenic reagents such as DTNB (Ellman's reagent) and DTP, allowing quantification of PLA2 activity. Isozyme-specific cPLA2 activity can be measured by depleting or inhibiting sPLA2 and iPLA2 activity in the assay.
|
-
- HY-116141
-
|
7-HCA; Umbelliferyl Arachidonate; 7-HC-arachidonate
|
Phospholipase
MAGL
|
Others
|
|
7-Hydroxycoumarinyl arachidonate (7-HCA) is a fluorogenic substrate of cytosolic phospholipase A2 (PLA2). 7-Hydroxycoumarinyl arachidonate is also a fluorogenic substrate for monoacylglycerol lipase (MAGL). MAGL protein catalyzes the hydrolysis of 7-Hydroxycoumarinyl arachidonat to generate Arachidonic acid (AA) and the highly fluorescent 7-hydroxyl coumarin (7-HC; HY-N0573). Release of 7-HC can be measured using a fluorometer .
|
-
- HY-100168R
-
|
|
Reference Standards
Phospholipase
|
Others
|
|
BAPTA (Standard) is the analytical standard of BAPTA. This product is intended for research and analytical applications. BBAPTA is a selective and cell-impermeant chelator for calcium. BAPTA, as calcium indicator, has high selectivity against magnesium and calcium. BAPTA is widely used as an intracellular buffer for investigating the effects of Ca 2+ release from intracellular stores or influx via Ca 2+-permeable channels in the plasma membrane. BAPTA can also inhibit phospholipase C activity independently of their role as Ca 2+ chelators .
|
-
- HY-108611
-
AACOCF3
4 Publications Verification
Arachidonyl trifluoromethyl ketone
|
Phospholipase
|
Cardiovascular Disease
|
|
AACOCF3 (Arachidonyl trifluoromethyl ketone) is a cell-permeant trifluoromethyl ketone analog of arachidonic acid. AACOCF3 is a potent and selective slow binding inhibitor of the 85-kDa cytosolic phospholipase A2 (cPLA2). AACOCF3 blocks production of arachidonate and 12-hydroxyeicosatetraenoic acid by calcium ionophore-challenged platelets. AACOCF3 inhibits glucose-induced insulin secretion from isolated rat islets. AACOCF3 has the potential for the research of cardiovascular disease .
|
-
- HY-108630R
-
|
|
Reference Standards
Phospholipase
|
Others
|
|
U-73343 (Standard) is the analytical standard of U-73343 (HY-108630). This product is intended for research and analytical applications. U-73343, works as a protonophore, is an inactive analog of U-73122 and can be used as a negative control. U-73343 dose-dependently inhibits acid secretion irrespective of the stimulant. U-73122 is a phospholipase C (PLC) and 5-LO (5-lipoxygenase) inhibitor with an IC50 of 1-2.1 μM for PLC .
|
-
- HY-13402S
-
|
LY315920-d7
|
Isotope-Labeled Compounds
Phospholipase
|
Inflammation/Immunology
|
|
Varespladib-d7 (LY315920-d7) is a deuterated labeled Varespladib (HY-13402). Varespladib is a potent and selective group IIA, secretory phospholipase A2 (sPLA2) inhibitor with an IC50 of 9 nM. Varespladib exhibits the significant inhibitory effect on sPLA2 activity in serum from various species including rat, rabbit, guinea pig and human with IC50s of 8.1 nM, 5.0 nM, 3.2 nM and 6.2 nM, respectively .
|
-
- HY-120078
-
|
|
Phospholipase
|
|
|
AZD2716 is a selective sPLA2 (secretory phospholipase A2) inhibitor. AZD2716 significantly reduces the production of pro-inflammatory lipids by inhibiting sPLA2-IIa (IC50 = 10 nM), sPLA2-V (IC50 = 40 nM), and sPLA2-X (IC50 = 400 nM), thereby decreasing macrophage activation and foam cell formation. AZD2716 is promising for studying mechanisms related to atherosclerosis and inflammatory diseases associated with sPLA2 .
|
-
- HY-N16849
-
|
YM 26567-1
|
COX
Prostaglandin Receptor
Fungal
|
Infection
Inflammation/Immunology
|
|
Myristinin A (YM 26567-1) is a trans-isomer flavan compound found in Horsfieldia amygdaline and Myristica cinnamomea. Myristinin A can selectively inhibit COX-2 activity with an IC50 of 16.9 μg/mL. Myristinin A can reduce the production of prostaglandin E2 (PGE2) and inhibit phospholipase A2 (PLA2), thereby blocking the release of inflammatory mediators. Myristinin A can inhibit Candida albicans with an IC50 of 8.8 μg/mL. Myristinin A can be used for the research of inflammation and infection, such as rheumatoid arthritis .
|
-
- HY-120050
-
|
|
Phospholipase
|
Inflammation/Immunology
|
|
GK470 (compound 28) is an inhibitor of group IVA cytosolic phospholipase A2 (GIVA cPLA2) with an IC50 of 300 nM in vesicle assays. GK470 has anti-inflammatory activity, inhibiting the release of arachidonic acid in SW982 fibroblast-like synoviocytes with an IC50 value of 0.6 μM. GK470 exhibits comparable anti-inflammatory effects to Methotrexate (HY-14519) in a preventive collagen-induced arthritis model and significantly reduces plasma PGE2 levels .
|
-
- HY-W403046A
-
|
|
Drug Metabolite
Calcium Channel
|
Neurological Disease
|
|
D-myo-Inositol-4-phosphate monoammonium is a metabolite of D-myo-Inositol 1,4,5-trisphosphate. D-myo-Inositol 1,4,5-trisphosphate, a second messenger, elicits Ca 2+ mobilization. D-myo-Inositol 1,4,5-trisphosphate inhibits the binding of phosphoinositide-specific phospholipase C-delta 1 (PLC-delta 1) to bilayer membranes composed of phosphatidylcholine (PC) and phosphatidylinositol 4,5-bisphosphate (PIP2) .
|
-
- HY-146925S
-
|
|
Isotope-Labeled Compounds
Endogenous Metabolite
|
Cardiovascular Disease
|
|
15:0 Lyso PC-d5 is deuterium labeled 15:0 Lyso PC (HY-W329357). 15:0 Lyso PC is a lysophosphatidylcholine (Lyso PC), a product of phospholipase A2 (PLA2) hydrolysis of phosphatidylcholine (PC) and is involved in cell membrane remodeling and inflammatory signaling. 15:0 Lyso PC demonstrates significant lipid metabolism disturbances in the serum of patients with ischemic heart disease (IHD) and ischemic cardiomyopathy (ICM). 15:0 Lyso PC can be used as a lipid biomarker for cardiovascular disease.
|
-
- HY-148123
-
|
|
Biochemical Assay Reagents
|
Neurological Disease
|
|
Glycerophospholipids and cephalins are a class of phospholipid compounds and important components of neural membranes. Glycerophospholipids and cephalins are hydrolysis substrates of phospholipase (such as PLA2, PLC, and PLD). After complete hydrolysis, they produce 1 mol of glycerol, phosphate, ethanolamine, and 2 mol of fatty acids, respectively. Glycerophospholipids and cephalins can maintain membrane structure, fluidity, and ion permeability, and serve as precursors of second messengers such as arachidonic acid and diacylglycerol. Glycerophospholipids and cephalins can regulate signal transduction, cell apoptosis, and membrane transport, and are used in the study of neurodegenerative diseases (such as Alzheimer's disease) .
|
-
- HY-101293R
-
|
CID-53361951 (Standard); ML-270 (Standard)
|
Phospholipase
Reference Standards
Fungal
|
Infection
Neurological Disease
Metabolic Disease
Inflammation/Immunology
Cancer
|
|
VU0359595 (Standard) is the analytical standard of VU0359595 (HY-101293). This product is intended for research and analytical applications. VU0359595 (CID-53361951; ML-270) is a potent and selective pharmacological phospholipase D1 (PLD1) inhibitor with an IC50 of 3.7 nM. VU0359595 is >1700-fold selective for PLD1 over PLD2 (IC50 of 6.4 μM). VU0359595 can be used for the research of cancer, diabetes, neurodegenerative and inflammatory diseases .
|
-
- HY-137603A
-
|
UTPγS tetrasodium
|
P2Y Receptor
|
Neurological Disease
Metabolic Disease
|
|
Uridine-5'-O-(3-thiotriphosphate) (UTPγS) tetrasodium, a stable analogue of Uridine triphosphate (UTP) (HY-107372), is a potent agonist of the P2Y2 and P2Y4 receptors with increased metabolic stability. Uridine-5'-O-(3-thiotriphosphate) tetrasodium stimulates inositol phosphate formation in human 1321N1 astrocytoma cells stably expressing the phospholipase C-coupled human P2U-purinoceptor (EC50 = 240 nM) .
|
-
- HY-100168AR
-
|
|
Reference Standards
Phospholipase
|
Others
|
|
BAPTA tetrasodium (Standard) is the analytical standard of BAPTA tetrasodium. This product is intended for research and analytical applications. BAPTA tetrasodium is a selective and cell-impermeant chelator for calcium. BAPTA tetrasodium, as calcium indicator, has high selectivity against magnesium and calcium. BAPTA tetrasodium is widely used as an intracellular buffer for investigating the effects of Ca 2+ release from intracellular stores or influx via Ca 2+-permeable channels in the plasma membrane. BAPTA tetrasodium can also inhibit phospholipase C activity independently of their role as Ca 2+ chelators .
|
-
- HY-173371
-
|
|
Phospholipase
|
Neurological Disease
|
|
BRI-50460 is an inhibitor of cytosolic calcium-dependent phospholipase A2 (cPLA2) that has the ability to penetrate the blood-brain barrier, with an IC50 of 0.88 nM. BRI-50460 exerts the activities of regulating neuroinflammation and restoring lipid homeostasis by inhibiting cPLA2, regulating the downstream inflammatory lipid signaling pathway, and alleviating the effects of amyloid β42 oligomers on the activation of cPLA2, the hyperphosphorylation of tau protein, and the reduction of synapses and dendrites. BRI-50460 can be applied to the research in the fields of Alzheimer's disease and other neurodegenerative diseases .
|
-
- HY-137603
-
|
UTPγS
|
P2Y Receptor
|
Metabolic Disease
|
|
Uridine-5'-O-(3-thiotriphosphate) (UTPγS), a stable analogue of Uridine triphosphate (UTP) (HY-107372), is a potent agonist of the P2Y2 and P2Y4 receptors with increased metabolic stability. Uridine-5'-O-(3-thiotriphosphate) stimulates inositol phosphate formation in human 1321N1 astrocytoma cells stably expressing the phospholipase C-coupled human P2U-purinoceptor (EC50 = 240 nM) .
|
-
- HY-14117
-
-
- HY-157718
-
|
|
Biochemical Assay Reagents
|
|
|
1,2-Di-O-(9Z-octadecenyl)-sn-glycero-3-phosphocholine is a surfactant that has the activity of promoting liposome formation. 1,2-Di-O-(9Z-octadecenyl)-sn-glycero-3-phosphocholine can effectively study the biological effects of ceramide and ceramide phosphate. 1,2-Di-O-(9Z-octadecenyl)-sn-glycero-3-phosphocholine shows important application in the determination of phospholipase A activity of lecithin-cholesterol acyltransferase in ether matrix.
|
-
- HY-N16865
-
|
|
COX
Prostaglandin Receptor
Fungal
|
Infection
Inflammation/Immunology
|
|
Myristinin B/C is a mixture of Myristinin B and Myristinin C. Myristinin B/C is a flavan compound found in Horsfieldia amygdaline and Myristica cinnamomea. Myristinin B/C can selectively inhibit COX-2 activity with an IC50 of 2.1 μg/mL. Myristinin B/C can reduce the production of prostaglandin E2 (PGE2) and inhibit phospholipase A2 (PLA2), thereby blocking the release of inflammatory mediators. Myristinin B/C can inhibit Candida albicans with an IC50 of 6 μg/mL. Myristinin B/C can be used for the research of inflammation and infection, such as rheumatoid arthritis .
|
-
- HY-100168BR
-
|
|
Reference Standards
Phospholipase
|
Others
|
|
BAPTA tetrapotassium (Standard) is the analytical standard of BAPTA tetrapotassium (HY-100168B). This product is intended for research and analytical applications. BAPTA tetrapotassium is a selective and cell-impermeant chelator for calcium. BAPTA tetrapotassium, as calcium indicator, has high selectivity against magnesium and calcium. BAPTA tetrapotassium is widely used as an intracellular buffer for investigating the effects of Ca 2+ release from intracellular stores or influx via Ca 2+-permeable channels in the plasma membrane. BAPTA tetrapotassium can also inhibit phospholipase C activity independently of their role as Ca 2+ chelators .
|
-
- HY-181446
-
|
|
Endogenous Metabolite
|
Others
|
|
PtdIns-(4,5)-P2 (1,2-dipalmitoyl) ammonium (PI(4,5)P2) is a signaling molecule. PtdIns-(4,5)-P2 (1,2-dipalmitoyl) ammonium is critical at multiple stages of endocytosis, where it sequentially recruits adaptor proteins and accessory proteins to endocytic sites. PtdIns-(4,5)-P2 (1,2-dipalmitoyl) ammonium is considered essential for maintaining the structure of the Golgi apparatus and the transport of proteins within the Golgi apparatus .
|
-
- HY-N1393R
-
|
NSC 3778 (Standard); O-Methylsalicylic acid (Standard); Salicylic acid methyl ether (Standard)
|
Reference Standards
Carbonic Anhydrase
Phospholipase
|
Cardiovascular Disease
|
|
2-Methoxybenzoic acid (NSC 3778; O-Methylsalicylic acid; Salicylic acid methyl ether) (Standard) is the analytical standard of 2-Methoxybenzoic acid (HY-N1393). 2-Methoxybenzoic acid is a natural compound with potential salicylate-like effect. 2-Methoxybenzoic acid inhibits carbonic anhydrase activity, elevates intraplatelet cyclic guanosine monophosphate level, and suppresses cytosolic phospholipase A2 phosphorylation. 2-Methoxybenzoic acid suppresses platelet reactivity, including decreased spreading, retraction, and aggregation in platelets. 2-Methoxybenzoic acid ameliorates arterial thrombosis in a dose-dependent manner without affecting normal hemostasis in mice. 2-Methoxybenzoic acid can be used for the research of arterial thrombosis .
|
-
- HY-19619R
-
|
|
Phospholipase
Apoptosis
|
Cancer
|
|
m-3M3FBS (Standard) is the analytical standard of m-3M3FBS. This product is intended for research and analytical applications. m-3M3FBS is a potent phospholipase C (PLC) activator. m-3M3FBS stimulates superoxide generation in human neutrophils, upregulates intracellular calcium concentration, and stimulates inositol phosphate generation in various cell lines. m-3M3FBS induces monocytic leukemia cell apoptosis .
|
-
- HY-135564A
-
|
|
Phosphatase
Phospholipase
HIV Protease
ERK
Autophagy
|
Infection
Cancer
|
|
RK-682 is the inhibitor for protein tyrosine phosphatase (PTPase), heparanase, phospholipase A2 and HIV-1 protease. RK-682 inhibits the dephosphorylation of CD45 (IC50 is 54 μM) and VHR (IC50 is 2.0 μM), and thereby inhibits the ERK signaling pathway. RK-682 inhibits the cell viability of cancer cell MGH-U3, T24 and UROtsa with IC50s of 78.2, 43.2 and 145 nM, respectively, arrests the cell cycle at G1/S phase, inhibits the cell migration and autophagy in MGH-U3 and T24 .
|
-
- HY-12246
-
XEN445
1 Publications Verification
|
Lipase
|
Cardiovascular Disease
Metabolic Disease
Cancer
|
|
XEN445 is a potent, selective and orally active endothelial lipase (EL) inhibitor with an IC50 value of 0.237 μM. XEN445 selectively inhibits phospholipase enzymatic activity of LIPG. XEN445 raises plasma HDL and cholesterol levles. XEN445 induces G1 cell cycle arrest, reduces cell viability, suppresses cancer stem cell self-renewal, and inhibits tumor formation in LIPG-expressing triple-negative breast cancer cells, while showing no inhibitory effect on invasiveness or cancer stem cell stemness in these cells. XEN445 can be used for the research of cancer and metabolic disease, such as triple-negative breast cancer .
|
-
- HY-N1393S1
-
|
NSC 3778-d3; O-Methylsalicylic acid-d3; Salicylic acid methyl ether-d3
|
Isotope-Labeled Compounds
Carbonic Anhydrase
Phospholipase
|
Cardiovascular Disease
|
|
2-Methoxybenzoic acid (NSC 3778; O-Methylsalicylic acid; Salicylic acid methyl ether)-d3 is deuterium-labeled 2-Methoxybenzoic acid (HY-N1393). 2-Methoxybenzoic acid is a natural compound with potential salicylate-like effect. 2-Methoxybenzoic acid inhibits carbonic anhydrase activity, elevates intraplatelet cyclic guanosine monophosphate level, and suppresses cytosolic phospholipase A2 phosphorylation. 2-Methoxybenzoic acid suppresses platelet reactivity, including decreased spreading, retraction, and aggregation in platelets. 2-Methoxybenzoic acid ameliorates arterial thrombosis in a dose-dependent manner without affecting normal hemostasis in mice. 2-Methoxybenzoic acid can be used for the research of arterial thrombosis .
|
-
- HY-114457
-
|
L-alpha-Phosphatidylinositol-4,5-bisphosphate; (PtdIns)-(4,5)-P2
|
Phospholipase
|
Inflammation/Immunology
|
|
Phosphatidylinositol 4,5-bisphosphate (L-alpha-Phosphatidylinositol-4,5-bisphosphate) is a plasma membrane lipid that is enriched in the cytoplasmic leaflet of the plasma membrane. Phosphatidylinositol 4,5-bisphosphate serves as a substrate for phospholipase C and class I PI3K, generating diacylglycerol, inositol (1,4,5)-trisphosphate, and phosphatidylinositol (3,4,5)-trisphosphate. Phosphatidylinositol 4,5-bisphosphate contributes to lamellipodial protrusion, directional cell migration, focal adhesion lipid generation, and trafficking of the GABAA receptor. Phosphatidylinositol 4,5-bisphosphate can be used in research related to acute lung injury and pulmonary edema .
|
-
- HY-N1393S
-
|
NSC 3778-13C6; O-Methylsalicylic acid-13C6; Salicylic acid methyl ether-13C6
|
Isotope-Labeled Compounds
Carbonic Anhydrase
Phospholipase
|
Cardiovascular Disease
|
|
2-Methoxybenzoic acid (NSC 3778; O-Methylsalicylic acid; Salicylic acid methyl ether)- 13C6 is the 13C-labeled 2-Methoxybenzoic acid (HY-N1393). 2-Methoxybenzoic acid is a natural compound with potential salicylate-like effect. 2-Methoxybenzoic acid inhibits carbonic anhydrase activity, elevates intraplatelet cyclic guanosine monophosphate level, and suppresses cytosolic phospholipase A2 phosphorylation. 2-Methoxybenzoic acid suppresses platelet reactivity, including decreased spreading, retraction, and aggregation in platelets. 2-Methoxybenzoic acid ameliorates arterial thrombosis in a dose-dependent manner without affecting normal hemostasis in mice. 2-Methoxybenzoic acid can be used for the research of arterial thrombosis .
|
-
- HY-175070
-
|
Ins(2,4,5)P3 sodium salt; 2,4,5-IP3 sodium salt
|
Calcium Channel
|
Metabolic Disease
|
|
D-myo-Inositol-2,4,5-triphosphate (Ins(2,4,5)P3) (sodium salt) is a second messenger produced in cells by phospholipase C-mediated hydrolysis of phosphatidylinositol-4,5-biphosphate. D-myo-Inositol-2,4,5-triphosphate (sodium salt) can open calcium channels and increase intracellular calcium upon binding to its receptors on the endoplasmic reticulum. D-myo-Inositol-2,4,5-triphosphate (sodium salt) also acts as a partial agonist at rat hepatic IP3 receptors. D-myo-Inositol-2,4,5-triphosphate (sodium salt) can be studied in research on calcium ions signaling pathway .
|
-
- HY-135564
-
|
|
Phosphatase
Phospholipase
HIV Protease
ERK
Autophagy
|
Infection
Cancer
|
|
RK-682 hemicalcium is the hemicalcium salt form of RK-682 (HY-135564A). RK-682 hemicalcium is the inhibitor for protein tyrosine phosphatase (PTPase), heparanase, phospholipase A2 and HIV-1 protease. RK-682 hemicalcium inhibits the dephosphorylation of CD45 (IC50 is 54 μM) and VHR (IC50 is 2.0 μM), and thereby inhibits the ERK signaling pathway. RK-682 hemicalcium inhibits the cell viability of cancer cell MGH-U3, T24 and UROtsa with IC50s of 78.2, 43.2 and 145 nM, respectively, arrests the cell cycle at G1/S phase, inhibits the cell migration and autophagy in MGH-U3 and T24 [2] .
|
-
- HY-182705
-
|
|
Estrogen Receptor/ERR
|
Endocrinology
|
|
Org 214444-0 is an orally active, nanomolar-potent and selective FSHR agonist, with EC50 values of 2.0 nM and 1.2 nM in human and rat (measured in CHO cells). Org 214444-0 activates human granulosa cells in vitro, supports rat follicular development and induces ovulation in vivo. Org 214444-0 can be used for the research of infertility .
|
-
- HY-150524
-
|
|
Endogenous Metabolite
P2Y Receptor
|
Metabolic Disease
|
|
UDP-Galactose is a monosaccharide and a key glycosyl donor molecule in cells that participates in nucleotide sugar metabolism. UDP-Galactose is the natural agonist of the P2Y14 receptor coupled to Gi proteins in the immune system (IC50 = 0.67 μM, hP2Y14). UDP-Galactose can be used to study cell signal transduction and substance metabolism .
|
-
- HY-115062
-
|
|
Phospholipase
NADPH Oxidase
p38 MAPK
Akt
NF-κB
AP-1
Reactive Oxygen Species (ROS)
|
Cardiovascular Disease
Inflammation/Immunology
Cancer
|
|
MJ-33 lithium salt is a competitive phospholipase A2 (PLA2) inhibitor with an IC50 of 0.3 μM. MJ-33 lithium salt inhibits NOX2 activation and reduces ROS production by blocking the PLA2 activity of Prdx6. MJ-33 lithium salt effectively inhibits the activity of acidic PLA2 (pH 4.0) and reduces the degradation of alveolar surfactant phosphatidylcholine (PC), but exerts no effect on alkaline PLA2 (pH 8.5). MJ-33 lithium salt significantly alleviates lung oxidative injury induced by ischemia-reperfusion (I/R). MJ-33 lithium salt significantly inhibits the invasion, migration and adhesion abilities of prostate cancer cells by suppressing the MAPK, AKT, NF-κB and AP-1 signaling pathways. MJ-33 lithium salt can be used for the research of ROS-related diseases and prostate cancer .
|
-
- HY-169262
-
|
|
Phospholipase
Apoptosis
|
Cancer
|
|
PLD-IN-1 (Compound 3r) is an orally active inhibitor for phospholipase D with an IC50 of 1.97 μM. PLD-IN-1 reduces the expression of CD24, CD47 and PD-L1, enhances the calreticulin expression, and thus modulates the immune evasion mechanism in lung cancer cells by promoting the phagocytosis of cancer cells by macrophages. PLD-IN-1 inhibits the cell viability of lung cancer cell A549, HCC44, H460 and HCC15 with IC50 of 18.44, 22.31, 24.85 and 21.45 μM, respectively. PLD-IN-1 can induce apoptosis and inhibits migration in cell A549. PLD-IN-1 enhances the level of pro-inflammatory M1 macrophages and decreases the level of anti-inflammatory M2 macrophages, exhibits antitumor efficacy in mouse model .
|
-
- HY-165397
-
|
|
PKC
|
Cardiovascular Disease
|
|
NA 0345 is a PKC inhibitor with IC50 values of 70 nM and 110 nM in the presence and absence of 12-O-tetradecanoyl-13-acetate, respectively. NA 0345 inhibits PKC and selectively suppresses the positive inotropic effect mediated by α1-adrenergic receptors .
|
-
- HY-49637
-
-
- HY-P99505
-
|
COR-001; MEDI-5117; MEDI-5117; NN-6018; WBP-216
|
Interleukin Related
LDLR
|
Inflammation/Immunology
Endocrinology
|
|
Ziltivekimab (COR-001) is a fully human monoclonal antibody and also an IL-6 inhibitor. Ziltivekimab significantly reduces inflammatory biomarkers and Lipoprotein (a) in chronic kidney disease patients with systemic inflammation. Ziltivekimab does not increase pro-atherosclerotic lipid levels. Ziltivekimab is used in studies related to atherosclerotic thrombotic diseases and chronic kidney disease .
|
-
- HY-W751375
-
|
|
Endogenous Metabolite
|
Others
|
|
Triricinolein is a triacylglycerol composed entirely of ricinoleic acid residues, and it is a fatty acid component of Malaysian castor oil .
|
-
- HY-103117
-
|
|
5-HT Receptor
|
Neurological Disease
|
|
S 32212 hydrochloride is an inverse agonist of 5-HT receptors 5-HT2(CINI) and 5-HT2(CVSV) (Kis=6.6, 8.9 nM) and an antagonist of 5-HT2A and α2β-adrenergic receptors (Ki=5.8, 5.8 nM). S 32212 hydrochloride can reduce the binding of GTPγS to Gαq, and reduce the activity of phospholipase C (PLC) in HEK293 cells expressing 5-HT2(CINI) receptor and CHO cells expressing 5-HT2(CVSV) receptor (EC50=38 and 18.6 nM, respectively). S 32212 hydrochloride (2.5 mg/kg) reduces 5-HT receptor agonist-induced head twitches and penile erections in mice and rats. S 32212 hydrochloride (10, 40 mg/kg) reduces immobility time in the forced swim test and marble burying behavior in mice and rats, exerting antidepressant and anxiolytic activities.
|
-
- HY-NP159
-
|
|
Mucin
Interleukin Related
|
Inflammation/Immunology
|
|
House Dust Mite Extract, from D.farinae is a house dust mite allergen extract derived from Dermatophagoides farinae. House Dust Mite Extract, from D.farinae significantly increases the levels of cytokines (IL-4, IL-5, IL-6) in bronchoalveolar lavage fluid. House Dust Mite Extract, from D.farinae upregulates the overexpression of MUC5AC. House Dust Mite Extract, from D.farinae induces allergic asthma and pulmonary inflammation .
|
-
- HY-107544
-
|
|
PKA
|
Metabolic Disease
|
|
8-pCPT-2'-O-Me-cAMP-AM is a cyclic AMP analogue, selectively activates Epac-Rap signaling pathway. 8-pCPT-2'-O-Me-cAMP-AM protects renal function by activating Epac from ischemia injury. 8-pCPT-2'-O-Me-cAMP-AM also stimulates insulin secretion by interaction with PKA pathway .
|
-
- HY-182295
-
|
|
Reactive Oxygen Species (ROS)
Apoptosis
MMP
Bacterial
Parasite
|
Cardiovascular Disease
Infection
Neurological Disease
|
|
Negundoside is an iridoid glycoside compound. Negundoside exhibits hepatoprotective effects, reduces ROS, lipid peroxidation and intracellular calcium ion levels, and prevents the decrease of mitochondrial membrane potential (MMP) and apoptosis (apoptosis). Negundoside has neuroprotective effects, improves behavioral deficits, alleviates oxidative damage, and ameliorates cerebral infarction. Negundoside also possesses antibacterial and antiparasitic activities .
|
-
| Cat. No. |
Product Name |
Type |
-
- HY-100045
-
|
4-Nitrophenylphosphorylcholine; 4-Nitrophenylphosphorylcholine; O-(4-Nitrophenylphosphoryl)choline
|
Fluorescent Dye
|
|
p-Nitrophenyl phosphorylcholine (4-Nitrophenylphosphorylcholine) is a chromogenic substrate that is used to measure phospholipase C (PLC) activity. Hydrolysis of p-nitrophenylphosphorylcholine by PLC results in the liberation of p-nitrophenol, which can be measured at 405 nm at pH 7.2-7.5.
|
-
- HY-D1647
-
|
|
Fluorescent Dye
|
|
7-Hydroxycoumarinyl-γ-linolenate is a cytosolic phospholipase A2 (cPLA2) fluorogenic substrate. 7-Hydroxycoumarinyl-γ-linolenate can be used to monitor the enzymatic activity of cPLA2 .
|
-
- HY-W713925
-
|
|
Fluorescent Dye
|
|
Diheptanoyl Thio-PC is a substrate for all phospholipase A2s (PLA2s) with the exception of cPLA2 and PAF-acetyl hydrolase (PAF-AH).1 Interaction of this compound with a PLA2 results in cleavage of the sn-2 fatty acid generating a free thiol on the lysophospholipid. This free thiol can be detected using chromogenic substrates such as DTNB (Ellman’s reagent) and DTP.
|
| Cat. No. |
Product Name |
Type |
-
- HY-100168
-
BAPTA
Maximum Cited Publications
36 Publications Verification
|
Biochemical Assay Reagents
|
|
BAPTA is a selective and cell-impermeant chelator for calcium. BAPTA has high selectivity against magnesium and calcium. BAPTA can also inhibit phospholipase C activity independently of their role as Ca 2+ chelators .
|
-
- HY-W039315
-
|
|
Biochemical Assay Reagents
|
2,5-Anhydro-D-mannitol, 97% is an antimetabolic fructose analogue. 2,5-Anhydro-D-mannitol, 97% depletes intracellular ATP, reduces oxygen consumption, regulates substrate oxidation, increases phosphomonoester levels, decreases inorganic phosphate levels, and promotes the release of intracellular calcium from intracellular calcium stores via phospholipase C-dependent activity in hepatocytes .
|
-
- HY-NP159
-
|
|
Biochemical Assay Reagents
|
|
House Dust Mite Extract, from D.farinae is a house dust mite allergen extract derived from Dermatophagoides farinae. House Dust Mite Extract, from D.farinae significantly increases the levels of cytokines (IL-4, IL-5, IL-6) in bronchoalveolar lavage fluid. House Dust Mite Extract, from D.farinae upregulates the overexpression of MUC5AC. House Dust Mite Extract, from D.farinae induces allergic asthma and pulmonary inflammation .
|
-
- HY-148123
-
|
|
Biochemical Assay Reagents
|
|
Glycerophospholipids and cephalins are a class of phospholipid compounds and important components of neural membranes. Glycerophospholipids and cephalins are hydrolysis substrates of phospholipase (such as PLA2, PLC, and PLD). After complete hydrolysis, they produce 1 mol of glycerol, phosphate, ethanolamine, and 2 mol of fatty acids, respectively. Glycerophospholipids and cephalins can maintain membrane structure, fluidity, and ion permeability, and serve as precursors of second messengers such as arachidonic acid and diacylglycerol. Glycerophospholipids and cephalins can regulate signal transduction, cell apoptosis, and membrane transport, and are used in the study of neurodegenerative diseases (such as Alzheimer's disease) .
|
-
- HY-100168B
-
|
|
Biochemical Assay Reagents
|
|
BAPTA tetrapotassium is a selective and cell-impermeant chelator for calcium. BAPTA has high selectivity against magnesium and calcium. BAPTA tetrapotassium can also inhibit phospholipase C activity independently of their role as Ca 2+ chelators .
|
-
- HY-W100403
-
|
Choline p-toluenesulfonate
|
Biochemical Assay Reagents
|
|
Choline tosylate (Choline p-toluenesulfonate) is an intermediate and also a substrate of choline acetyltransferase (CHAT). Choline tosylate inhibits phospholipase A2 and phospholipase C .
|
-
- HY-W329357
-
|
|
Biochemical Assay Reagents
|
|
15:0 Lyso PC is a lysophosphatidylcholine (Lyso PC), a product of phospholipase A2 (PLA2) hydrolysis of phosphatidylcholine (PC) and is involved in cell membrane remodeling and inflammatory signaling. 15:0 Lyso PC demonstrates significant lipid metabolism disturbances in the serum with ischemic heart disease (IHD) and ischemic cardiomyopathy (ICM). 15:0 Lyso PC can be used as a lipid biomarker for cardiovascular disease .
|
-
- HY-W127380
-
|
|
Biochemical Assay Reagents
|
|
Arachidonoyl Thio-PC is a substrate of many phospholipase A2 (PLA2), including sPLA2, cPLA2 and iPLA2. Cleavage of sn-2 fatty acids by PLA2 results in the production of free thiols, which react with chromogenic reagents such as DTNB (Ellman's reagent) and DTP, allowing quantification of PLA2 activity. Isozyme-specific cPLA2 activity can be measured by depleting or inhibiting sPLA2 and iPLA2 activity in the assay.
|
-
- HY-W414749
-
|
1-Octanoyl-sn-glycero-3-phosphocholine
|
Biochemical Assay Reagents
|
|
08:0 Lyso PC (1-Octanoyl-sn-glycero-3-phosphocholine) is a lysolecithin that can be hydrolyzed by Phospholipase A2 (HY-P3029) .
|
-
- HY-100168R
-
|
|
Biochemical Assay Reagents
|
|
BAPTA (Standard) is the analytical standard of BAPTA. This product is intended for research and analytical applications. BBAPTA is a selective and cell-impermeant chelator for calcium. BAPTA, as calcium indicator, has high selectivity against magnesium and calcium. BAPTA is widely used as an intracellular buffer for investigating the effects of Ca 2+ release from intracellular stores or influx via Ca 2+-permeable channels in the plasma membrane. BAPTA can also inhibit phospholipase C activity independently of their role as Ca 2+ chelators .
|
-
- HY-157718
-
|
|
Biochemical Assay Reagents
|
|
1,2-Di-O-(9Z-octadecenyl)-sn-glycero-3-phosphocholine is a surfactant that has the activity of promoting liposome formation. 1,2-Di-O-(9Z-octadecenyl)-sn-glycero-3-phosphocholine can effectively study the biological effects of ceramide and ceramide phosphate. 1,2-Di-O-(9Z-octadecenyl)-sn-glycero-3-phosphocholine shows important application in the determination of phospholipase A activity of lecithin-cholesterol acyltransferase in ether matrix.
|
-
- HY-100168BR
-
|
|
Biochemical Assay Reagents
|
|
BAPTA tetrapotassium (Standard) is the analytical standard of BAPTA tetrapotassium (HY-100168B). This product is intended for research and analytical applications. BAPTA tetrapotassium is a selective and cell-impermeant chelator for calcium. BAPTA tetrapotassium, as calcium indicator, has high selectivity against magnesium and calcium. BAPTA tetrapotassium is widely used as an intracellular buffer for investigating the effects of Ca 2+ release from intracellular stores or influx via Ca 2+-permeable channels in the plasma membrane. BAPTA tetrapotassium can also inhibit phospholipase C activity independently of their role as Ca 2+ chelators .
|
| Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-P10447
-
|
Fengycin IX; SNA-60-367-3
|
Phospholipase
Fungal
|
Infection
|
|
Plipastatin A1 (Fengycin IX; SNA-60-367-3) is a lipopeptide with phospholipase A2 inhibitory activity. Plipastatin A1 inhibits conidial germination of Botrytis cinerea in vitro and reduces the incidence of gray mold on tomato leaves. Plipastatin A1 is applicable to research related to gray mold [1][2].
|
-
- HY-P1341
-
|
Orexin A (17-33) (human, mouse, rat, bovine)
|
Orexin Receptor (OX Receptor)
Sigma Receptor
Phospholipase
|
Neurological Disease
|
|
OXA (17-33) (Orexin A (17-33) (human, mouse, rat, bovine)) is the shortest active orexin peptide that selectively targets OX1 (EC50=8.29 nM), with 23-fold selectivity for the OX1 receptor over the OX2 receptor. The activity of OXA (17-33) depends on the Tyr17, Leu20, Asn25, His26 residues and the spatial conformation of the α-helix. OXA (17-33) activates signaling pathways involving inositol-1,4,5-trisphosphate receptor (IP3R), phospholipase D (PL-D) and choline-Sigma-1R, thereby increasing the cytoplasmic Ca 2+ level in nucleus accumbens neurons, an effect that is blocked by Sigma-1R antagonists. OXA (17-33) serves as an important biological probe for investigating the function of the OX1 receptor. OXA (17-33) can be modified via incorporation of mixed disulfide bonds of homocysteine and cysteamine, and is widely used in studies related to insomnia and narcolepsy .
|
-
- HY-P2705
-
|
|
Endogenous Metabolite
|
Others
|
|
Mastoparan X is a GTP-binding regulatory protein (G protein)-activating peptide, and a tetradecapeptide from wasp venom. Mastoparan X acts function by the direct activation of G protein that couple to phospholipase C to cause secretion from various kinds of cells .
|
-
- HY-P10053
-
|
|
Phospholipase
|
Metabolic Disease
|
|
sPLA2-IIA Inhibitor is a cyclic pentapeptide analog of FLSYK (cyclic 2-Nal-Leu-Ser-2-Nal-Arg (c2)), that binds to hGIIA (human IIA phospholipase A2) and inhibits its hydrolytic ability. sPLA2 is a member of the esterase superfamily that catalyzes the hydrolysis of the ester bond at the sn-2 position of glycerophospholipids, releasing free fatty acids such as arachidonic acid and lysophospholipids .
|
-
- HY-P3906
-
|
|
Fungal
Apoptosis
Phospholipase
Reactive Oxygen Species (ROS)
|
Infection
|
|
Melittin free acid is a basic 26-amino-acid polypeptide, the major active ingredient of honeybee venom. Melittin free acid is an activator of phospholipase A2 (PLA2). Melittin free acid has broad-spectrum antifungal activity with MIC values of 0.4-60 μM. Melittin free acid hinders fungal growth by inducing cell apoptosis, repressing (1,3)-β-D-glucan synthase and participating in other pathways .
|
-
- HY-113560
-
-
- HY-P10658
-
|
|
Phospholipase
|
Others
|
|
ARF1 (2-17) inhibits both ARF-independent (PLC-β) and ARF-dependent (PLD) pathways. ARF1 (2-17) inhibits GTP-γ-S-stimulated PLD activity, phospholipase C-β (PLC-β), and exocytosis .
|
-
- HY-P1834
-
|
|
Peptides
|
Inflammation/Immunology
|
|
MARCKS Peptide(151-175), Phosphorylated is a phosphorylated peptide corresponding to the basic effector domain of myristoylated alanine-rich protein kinase C substrate protein (MARCKS). Phosphorylation of MARCKS Peptide (151-175) reverses its inhibition of phospholipase C (PLC)-catalyzed hydrolysis of phosphatidylinositol 4,5-bisphosphate (PIP2) .
|
-
- HY-P2139
-
|
|
Neurokinin Receptor
Phospholipase
|
Others
|
|
Ranakinin is a NK1R agonist. Ranakinin inhibits the binding of selective NK1 radioligands to NK1 receptors. Ranakinin activates phospholipase C (Phospholipase C), thereby enhancing polyphosphoinositide hydrolysis. Ranakinin stimulates inositol phosphate production and reduces membrane polyphosphoinositide levels. Ranakinin stimulates corticosterone and aldosterone secretion .
|
| Cat. No. |
Product Name |
Target |
Research Area |
Image |
-
- HY-P99505
-
|
COR-001; MEDI-5117; MEDI-5117; NN-6018; WBP-216
|
Interleukin Related
LDLR
|
Inflammation/Immunology
Endocrinology
|
|
Ziltivekimab (COR-001) is a fully human monoclonal antibody and also an IL-6 inhibitor. Ziltivekimab significantly reduces inflammatory biomarkers and Lipoprotein (a) in chronic kidney disease patients with systemic inflammation. Ziltivekimab does not increase pro-atherosclerotic lipid levels. Ziltivekimab is used in studies related to atherosclerotic thrombotic diseases and chronic kidney disease .
|
-
(5)
-
- HY-P991964
-
|
Rendomab-B49
|
Endothelin Receptor
|
Cancer
|
|
Rendomab B4 is a monoclonal antibody targeting ETB. Rendomab B4 preferentially binds to ETB in the active conformational state and exhibits selectivity for ETB on melanoma cells. Rendomab B4 inhibits the G protein-dependent phospholipase C (PLC) pathway, blocks ET-3-induced Gαi/o-mediated inhibition of adenylate cyclase, and does not affect the activation of the ERK1/2 pathway. Rendomab B4 is applicable to melanoma-related research .
|
-
(5)
| Cat. No. |
Product Name |
Category |
Target |
Chemical Structure |
-
- HY-B0470
-
-
-
- HY-W019838
-
-
-
- HY-136177
-
-
-
- HY-N9480
-
-
-
- HY-N7036
-
-
-
- HY-N1393
-
-
-
- HY-W012595
-
-
-
- HY-N7327
-
|
|
Structural Classification
Flavonoids
Ochna atropurpurea DC.
Plants
Biflavones
Source Classification
|
Phospholipase
|
|
Ochnaflavone is an inhibitor of IIA-type secretory phospholipase A2 (sPLA2-IIA) with an IC50 of 3.45 µM. Ochnaflavone exhibits significant anti-inflammatory and liver-protective effects, capable of inhibiting the degradation of phosphatidylethanolamine (PE) and lipid peroxidation induced by carbon tetrachloride (CCl4) in rat liver, with an IC50 of 7.16 µM for lipid peroxidation. Ochnaflavone can be used in research on liver damage and inflammatory diseases .
|
-
-
- HY-150524
-
-
-
- HY-N1773
-
-
-
- HY-114457
-
|
L-alpha-Phosphatidylinositol-4,5-bisphosphate; (PtdIns)-(4,5)-P2
|
Structural Classification
Human Gut Microbiota Metabolites
Classification of Application Fields
Other Diseases
Endogenous metabolite
Disease Research Fields
Lipid
Source Classification
|
Phospholipase
|
|
Phosphatidylinositol 4,5-bisphosphate (L-alpha-Phosphatidylinositol-4,5-bisphosphate) is a plasma membrane lipid that is enriched in the cytoplasmic leaflet of the plasma membrane. Phosphatidylinositol 4,5-bisphosphate serves as a substrate for phospholipase C and class I PI3K, generating diacylglycerol, inositol (1,4,5)-trisphosphate, and phosphatidylinositol (3,4,5)-trisphosphate. Phosphatidylinositol 4,5-bisphosphate contributes to lamellipodial protrusion, directional cell migration, focal adhesion lipid generation, and trafficking of the GABAA receptor. Phosphatidylinositol 4,5-bisphosphate can be used in research related to acute lung injury and pulmonary edema .
|
-
-
- HY-W612338
-
|
9-ONA
|
Structural Classification
Arachis hypogaea L.
Leguminosae
Ketones, Aldehydes, Acids
Plants
Source Classification
|
Acetyl-CoA Carboxylase
|
|
9-Oxononanoic acid (9-ONA) is an orally active acetyl-CoA carboxylase inhibitor. 9-Oxononanoic acid inhibits acetyl-CoA carboxylase via accumulation of long-chain acyl-CoA. 9-Oxononanoic acid increases carnitine palmitoyltransferase, isocitrate dehydrogenase and glucose 6-phosphate dehydrogenase activity to elevate β-oxidation and support NADPH (HY-113324) supplyactivity. 9-Oxononanoic acid stimulates phospholipase A2 activity via post-translational, non-transcriptional mechanisms. 9-Oxononanoic acid can be used for the research of atherothrombosis .
|
-
-
- HY-W012595A
-
-
-
- HY-B0470R
-
-
-
- HY-N2330
-
|
|
Microorganisms
Ketones, Aldehydes, Acids
Source Classification
|
Lipase
|
|
Lipstatin is a pancreatic lipase inhibitor (IC50=0.14 μM), whose structure is closely related to the known inhibitor, Esterastin. Lipstatin inhibits the absorption of triglycerides without affecting the absorption of oleic acid. Lipstatin has no inhibitory effects on other pancreatic enzymes, such as phospholipase A2 and trypsin (<200 μM) .
|
-
-
- HY-W654264
-
-
-
- HY-N1450
-
-
-
- HY-N8610
-
-
-
- HY-118725
-
-
-
- HY-136177R
-
-
-
- HY-116671
-
-
-
- HY-N14050
-
-
-
- HY-N14292
-
-
-
- HY-N14101
-
-
-
- HY-W019838R
-
-
-
- HY-N14103
-
-
-
- HY-N14104
-
-
-
- HY-N14105
-
-
-
- HY-N1450R
-
-
-
- HY-N7036R
-
-
-
- HY-W012595AR
-
-
-
- HY-N16481
-
-
-
- HY-W012595R
-
-
-
- HY-N1393R
-
|
NSC 3778 (Standard); O-Methylsalicylic acid (Standard); Salicylic acid methyl ether (Standard)
|
Structural Classification
Microorganisms
Ketones, Aldehydes, Acids
Endogenous metabolite
Source Classification
|
Reference Standards
Carbonic Anhydrase
Phospholipase
|
|
2-Methoxybenzoic acid (NSC 3778; O-Methylsalicylic acid; Salicylic acid methyl ether) (Standard) is the analytical standard of 2-Methoxybenzoic acid (HY-N1393). 2-Methoxybenzoic acid is a natural compound with potential salicylate-like effect. 2-Methoxybenzoic acid inhibits carbonic anhydrase activity, elevates intraplatelet cyclic guanosine monophosphate level, and suppresses cytosolic phospholipase A2 phosphorylation. 2-Methoxybenzoic acid suppresses platelet reactivity, including decreased spreading, retraction, and aggregation in platelets. 2-Methoxybenzoic acid ameliorates arterial thrombosis in a dose-dependent manner without affecting normal hemostasis in mice. 2-Methoxybenzoic acid can be used for the research of arterial thrombosis .
|
-
-
- HY-113507
-
-
-
- HY-N16849
-
-
-
- HY-N16865
-
-
| Cat. No. |
Product Name |
Chemical Structure |
-
- HY-W019838S
-
|
|
|
D-Erythro-dihydrosphingosine-d7 is the deuterium labeled D-Erythro-dihydrosphingosine. D-Erythro-dihydrosphingosin directly inhibits cytosolic phospholipase A2α (cPLA2α) activity.
|
-
-
- HY-13402S
-
|
|
|
Varespladib-d7 (LY315920-d7) is a deuterated labeled Varespladib (HY-13402). Varespladib is a potent and selective group IIA, secretory phospholipase A2 (sPLA2) inhibitor with an IC50 of 9 nM. Varespladib exhibits the significant inhibitory effect on sPLA2 activity in serum from various species including rat, rabbit, guinea pig and human with IC50s of 8.1 nM, 5.0 nM, 3.2 nM and 6.2 nM, respectively .
|
-
-
- HY-117068S
-
|
|
|
(R)-Bromoenol lactone-d7 ((R,E)-Bromoenol lactone-d7) is deuterium labeled (R)-Bromoenol lactone. (R)-Bromoenol lactone ((R)-BEL) is an irreversible, chiral, mechanism-based inhibitor of calcium-independent phospholipase γ (iPLA2γ). (R)-BEL inhibits human recombinant iPLA2γ with an IC50 of approximately 0.6 μM .
|
-
-
- HY-146925S
-
|
|
|
15:0 Lyso PC-d5 is deuterium labeled 15:0 Lyso PC (HY-W329357). 15:0 Lyso PC is a lysophosphatidylcholine (Lyso PC), a product of phospholipase A2 (PLA2) hydrolysis of phosphatidylcholine (PC) and is involved in cell membrane remodeling and inflammatory signaling. 15:0 Lyso PC demonstrates significant lipid metabolism disturbances in the serum of patients with ischemic heart disease (IHD) and ischemic cardiomyopathy (ICM). 15:0 Lyso PC can be used as a lipid biomarker for cardiovascular disease.
|
-
-
- HY-N1393S
-
|
|
|
2-Methoxybenzoic acid (NSC 3778; O-Methylsalicylic acid; Salicylic acid methyl ether)- 13C6 is the 13C-labeled 2-Methoxybenzoic acid (HY-N1393). 2-Methoxybenzoic acid is a natural compound with potential salicylate-like effect. 2-Methoxybenzoic acid inhibits carbonic anhydrase activity, elevates intraplatelet cyclic guanosine monophosphate level, and suppresses cytosolic phospholipase A2 phosphorylation. 2-Methoxybenzoic acid suppresses platelet reactivity, including decreased spreading, retraction, and aggregation in platelets. 2-Methoxybenzoic acid ameliorates arterial thrombosis in a dose-dependent manner without affecting normal hemostasis in mice. 2-Methoxybenzoic acid can be used for the research of arterial thrombosis .
|
-
-
- HY-N1393S1
-
|
|
|
2-Methoxybenzoic acid (NSC 3778; O-Methylsalicylic acid; Salicylic acid methyl ether)-d3 is deuterium-labeled 2-Methoxybenzoic acid (HY-N1393). 2-Methoxybenzoic acid is a natural compound with potential salicylate-like effect. 2-Methoxybenzoic acid inhibits carbonic anhydrase activity, elevates intraplatelet cyclic guanosine monophosphate level, and suppresses cytosolic phospholipase A2 phosphorylation. 2-Methoxybenzoic acid suppresses platelet reactivity, including decreased spreading, retraction, and aggregation in platelets. 2-Methoxybenzoic acid ameliorates arterial thrombosis in a dose-dependent manner without affecting normal hemostasis in mice. 2-Methoxybenzoic acid can be used for the research of arterial thrombosis .
|
-
| Cat. No. |
Product Name |
|
Classification |
-
- HY-W800785
-
|
1-palMitoyl-2-(10,12-tricosadiynoyl)-sn-glycero-3-phosphocholine
|
|
Phospholipids
|
|
16:0-23:2 Diyne PC is a phospholipase-mediated hydrolyzed phosphocoline with palmitic acid (16:0) and Pentacosa-10,12-diynoic acid for tails.
|
-
- HY-W800784
-
|
|
|
Phospholipids
|
|
23:2 Diyne PE [DC(8,9)PE] is a phospholipase-mediated hydrolyzed phosphocoline with palmitic acid (16:0) and Pentacosa-10,12-diynoic acid for tails.
|
-
- HY-157718
-
|
|
|
Phospholipids
|
|
1,2-Di-O-(9Z-octadecenyl)-sn-glycero-3-phosphocholine is a surfactant that has the activity of promoting liposome formation. 1,2-Di-O-(9Z-octadecenyl)-sn-glycero-3-phosphocholine can effectively study the biological effects of ceramide and ceramide phosphate. 1,2-Di-O-(9Z-octadecenyl)-sn-glycero-3-phosphocholine shows important application in the determination of phospholipase A activity of lecithin-cholesterol acyltransferase in ether matrix.
|
Your information is safe with us. * Required Fields.
Inquiry Information
- Product Name:
- Cat. No.:
- Quantity:
- MCE Japan Authorized Agent: